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See now the power of truth; the same experiment which at first glance seemed to show 
one thing, when more carefully examined, assures us of the contrary. 
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 Sphingolipids are a complex family of molecules that participate in many aspects 
of cell structure and function, including an essential cellular process known as autophagy. 
Autophagy is a degradation and recycling pathway whereby intracellular components are 
sequestered into double-membrane vesicles, known as autophagosomes, for subsequent 
fusion with lysosomes and degradation.  Autophagy takes part in cell survival, host 
immune defense against pathogens, and other biological processes, but is also sometimes 
lethal. Ceramide, sphingosine 1-phosphate, and more recently dihydroceramide have 
been shown to induce autophagy, which opens an interesting new field of cell regulation 
by sphingolipids. This dissertation describes two new cases in which sphingolipids 
participate in the induction of autophagy:  a) RAW264.7 cells treated with Kdo2-Lipid A, 
a lipopolysaccharide sub-structure with endotoxin activity equal to LPS; and b) MCF7 
cells treated with fenretinde, a chemotherapeutic agent which has shown success in 
clinical trials. It also analyzes the structural properties of fenretinide that contribute to its 
ability to modulate sphingolipid metabolism through inhibition of dihydroceramide 
desaturase, thereby elevating dihydroceramide and induction of autophagy. Autophagy 
was monitored by following the redistribution of GFP-LC3 into discrete punctate vesicles 
in response to the agents and by Western blotting; in parallel, the sphingolipid 
composition of the cells was monitored by liquid chromatography, electrospray 
ionization tandem mass spectrometry.  These analyses revealed that Kdo2-Lipid A and 
fenretinide induce profound changes in sphingolipid metabolism in RAW264.7 and 
MCF7 cells, respectively, and that one of the purposes for increased de novo biosynthesis 
 xvii 
is to enable the production of autophagosomes, as the autophagic response was inhibited 
by myriocin.    
These studies have uncovered a direct link between sphingolipid metabolism and 
autophagy, which could pave the way for new therapeutic interventions for the treatment 
of pathogenic infection and be clinically useful in enhancing the efficacy of current cancer 





SPHINGOLIPIDS: STRUCTURE, SYNTHESIS, AND SIGNALING 
1.1 Structural Diversity of Sphingolipid Species 
Sphingolipids (SL) are a complex family of phospho- and glycolipids found in 
essentially all eukaryotic and some prokaryotic organisms and viruses, as components of 
membranes and other biological structures where they influence cell structure, signaling, 
and interactions with the extracellular environment [1, 2]. SL are comprised of novel 
amine-containing sphingoid base backbones (2-aminoalka[ane or ene] 1,3 diols) that are 
distinguishable by chain length, the number of double bonds, and the presence of 
additional hydroxyls using the nomenclature depicted in Fig. 1.1 [1]. The diversity of 
sphingoid base backbones varies across different organisms with humans having 
primarily sphinganine (Sa), sphingosine (So), and 4-hydroxysphinganine 
(phytosphingosine) (Fig. 1.1) [1].  The sphingoid base backbone may be unmodified, 
phosphorylated, glycosylated, or otherwise modified through the addition of various 
headgroups at the primary hydroxyl and (or) an amide-linked fatty acid typically ranging 
from 14-30 carbons in length that is usually saturated, or with a single double bond (Fig. 
1.1) [1, 2]. Due to the combinatorial nature of SL biosynthesis, these backbone, 
headgroup, and acyl chain variations give rise to tens of thousands of mammalian SL 
species (www.sphingomap.org), and knowledge about the types and amounts of these 
subspecies can be imperative to understanding both the intracellular and extracellular 
signaling consequences of various stimuli, including immune effectors and 
chemotherapeutic agents as discussed herein [2].  
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Figure 1.1 Representative Structures of Sphingoid Base Backbones and Modifications 
Abbreviations: d18:0, dihydroxysphingoid base with two hydroxyl groups, 18 carbons, and no double 
bonds; d18:1, dihydroxysphingoid base with two hydroxyl groups, 18 carbons, and one double bond; 
t18:0 trihydroxysphingoid base with three hydroxyl groups, 18 carbons and no double bonds; Glc, 
glucose; Gal, galactose. After the addition of an amide linked fatty acid to form a (dihydro)ceramide 
species, the sphingoid base notation is followed by a semicolon or slash and identification of the 
carbon chain length and number of double bonds contained in the attached fatty acid, as shown for 
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N-palmitoylsphingosine (C16 Cer, d18:1/C16)
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1.2     Synthesis of Sphingolipid Species 
1.2.1  De novo Biosynthetic Pathway 
A significant portion of SL is derived from de novo biosynthesis in most 
organisms [3]. As a result, the first enzyme of the pathway serine palmitoyltransferase 
(SPT) is essential for the survival of cells in culture [3-5] and elimination of this enzyme 
has been found to be embryonic lethal for mice [3, 6] and fruit flies [3, 7].  As shown in 
Figure 1.2, SL biosynthesis de novo begins with the condensation of L-serine and 
palmitoyl-CoA to form 3-ketosphinganine (3KSa) catalyzed by SPT [1, 8]. This is 
followed by the rapid reduction of 3KSa to Sa by 3-ketosphinganine reductase (3KSR) 
[1, 9].  Sa is then phosphorylated by sphingosine kinase (SphK) to form sphinganine 1-
phosphate (Sa1P) [3, 10] or N-acylated by a family of (dihydro)ceramide synthases 
(CerS) [3, 11].  To date, six CerS have been identified [1, 3, 12]. Each of these enzymes 
utilizes fatty acyl-CoA substrates of relatively defined chain lengths, as depicted in Fig. 
1.2, resulting in the formation of distinct dihydroceramide (DHCer) subspecies [1, 13] 
which are, in most cases, desaturated by dihydroceramide desaturase (DES), resulting in 
the formation of ceramides (Cer) with acyl chains of various lengths [1, 14, 15]. Cer 
serves as the major branchpoint for the formation of more complex SL species [3], such 
as, sphingomyelin (SM) (through the addition of a phosphoryl choline headgroup by 
sphingomyelin synthase (SMS) [16-18]), Cer 1-phosphate (Cer1P), (via phosphorylation 
by ceramide kinase (CERK) [19, 20]), and monohexosylceramides (MH-Cer), 
(specifically glucosylceramide (GlcCer) and galactosylceramide (GalCer), through the 
addition of glucose or galactose from a sugar nucleotide by UDP-Glc:Cer 
glucosyltransferase (GlcCer synthase) or UDP-Gal:Cer galactosyltransferase (GalCer 
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synthase), respectively [3, 21, 22], which serve as precursors for the formation of 
hundreds of complex glycosphingolipids (GSL) [3]). Although, the majority of DHCer is 
desaturated to form Cer, it is worth noting that SMS [18], CERK [20], GlcCer synthase 
[23], and GalCer synthase [24] can accept DHCer subspecies as substrates in order to 
form the corresponding dihydrosphingolipids (DHSL), as depicted in Fig. 1.2. 
1.2.2  Turnover Pathway 
 Cellular metabolic homeostasis of the sphingolipidome is often achieved through 
the coordinate biosynthesis and removal of SL species requiring a delicate balance 
between de novo biosynthesis, turnover, and recycling [3]. Therefore, in addition to de 
novo biosynthesis, (DH)Cer may also be produced from the breakdown or turnover of 
complex SL via the action of specific hydrolases, including sphingomyelinases, 
glycohydrolases, and lipid phosphatases (Fig. 1.2) [1].  (DH)Cer can also be further 
metabolized by the action of ceramidases, which catalyze the hydrolysis of (DH)Cer into 
the free fatty acid and the sphingoid base, Sa or So (Fig. 1.2) [1, 25-29]. The produced Sa 
and/or So is then subject to one of two fates: 1) it can be recycled via reacylation for 
entry back into the SL pathway [1, 30] or 2) it can be phosphorylated by SphK producing 
sphinganine 1-phosphate (Sa1P) or sphingosine 1-phosphate (S1P) [1, 31]. In turn, the 
sphingoid base phosphate can be de-phosphorylated through the action of specific 
phosphatases [1, 32] or irreversibly degraded through the action of sphingosine 1-
phosphate lyase (lyase) to form ethanolamine phosphate and hexadec(an/en)al [1, 3, 33], 






Figure 1.2 Sphingolipid Metabolism Pathways for de novo biosynthesis and turnover are shown as 
described in the text. Key: Sphingoid bases are depicted as (dx:y). Fatty acyl chains are depicted as 
(cx:y). Abbreviations: SPT, serine palmitoyltransferase; 3KSaR, 3-ketosphinganine reductase; SphK, 
sphingosine kinase; CerS, ceramide synthase; DHSM, dihydrosphingomylin; DHCerP, 
dihydroceramide phosphate; DHCer, dihydroceramide; GlcDH, glucosyldihydroceramide; GalDH, 
galactosyldihyroceramide; SM, sphingomyelin; CerP, ceramide phosphate; Cer, ceramide; Glc, 
glucosylceramide; Gal, galactosylceramide. Different sphingolipid species are identified as follows: 
green octagon, (DH)Cer; heavy black boxes, (DH)SM; thin gray boxes, (DH)CerP; blue circles, 
glucosyl(DH)Cer; and yellow circles, galactosyl(DH)Cer. This figure was adapted from [3]. 
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1.2.3  Subcellular Localization of Sphingolipid Biosynthesis and Turnover 
 As shown in Figure 1.3, the enzymatic reactions of SL biosynthesis and turnover 
are distributed throughout various cellular compartments. SL biosynthesis de novo begins 
on the cytoplasmic surface of the endoplasmic reticulum (ER) [1, 9, 35]. Once formed in 
this compartment, Cer is trafficked to the Golgi complex (GC), where it can be converted 
into SM, Cer1P, and GlcCer, which serves as a precursor for more complex GSL [1]. 
Two distinct trafficking pathways have emerged for the transport of Cer from the ER to 
the GC [1, 35, 36]. Ceramide transfer protein (CERT) mediates the ER-to-GC trafficking 
of Cer via a suggested non-vesicular transport mechanism to the cis and medial GC for 
the synthesis of SM [1, 35-37] and to the trans-GC for the synthesis of Cer1P [3, 38]. A 
second vesicular transport pathway exists for the delivery of Cer to the GC for the 
synthesis of GlcCer [35, 36, 39].  In turn, GlcCer is transported by the recently identified 
golgi-associated four-phosphate adaptor protein 2 (FAPP2) to the distal golgi 
compartments for the synthesis of complex GSL [3, 35, 36, 40]. SM, CerP, and GSL are 
then trafficked from the GC to the plasma membrane through a vesicular transport 
mechanism where they become important components of plasma membrane structure and 
participate in numerous signaling events [3, 35, 41, 42]. In contrast to SM, Cer1P, and 
GlcCer, GalCer is synthesized from Cer in the lumen of the ER where it can be further 
diversified by sulfation into sulfatides [3, 43], which are trafficked to the plasma 
membrane where they participate in cell adhesion [3, 44].  
 The plasma membrane serves as one site for the turnover of SM, Cer1P, and GSL 
to Cer, as well as the downstream metabolites So and S1P [35]. SM and GSL can also be 
trafficked from the plasma membrane to other intracellular compartments such as the 
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lysosome, via the endocytic pathway, where they can be degraded by the action of 
sphingomyelinases and glucosidases to form Cer, which is further metabolized to So [1, 
27]. The newly formed So is able to exit the lysosome and shows adequate cytosolic 
solubility to move between membranes including the ER, where it can be recycled for 
continued SL biosynthesis [35]. Additionally, Cer (and possibly other SLs) have recently 
been found to be components of intracellular membraneous vacuoles known as 
autophagosomes [3, 45], which acquire of lysosomal hydrolases in order to become 
autophagolysosomes as part of their degradation mechanism [3]. Therefore, it is likely 
that this compartment serves as another site of Cer hydrolysis [3]. 
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Figure 1.3 Schematic Representation of the Trafficking and Compartmentalization of 
Sphingolipid Metabolism This diagram shows the de novo biosynthetic pathway beginning in the ER 
with the condensation of serine and palmitoyl-CoA and leading to the formation of Cer. Cer may then 
be subject to several different fates:  (1)  It may be transported to the golgi via CERT-mediated 
trafficking for the synthesis of SM or Cer1P. (2) It may be delivered to the golgi via vesicular 
transport for the synthesis of GlcCer followed by the transfer of GlcCer to the lumen of the distal golgi 
via the action of FAPP2 for complex GSL biosynthesis. (3) It may be transported to the lumen of the 
ER for synthesis of GalCer. or (4) It may be incorporated into other intracellular compartments such as 
autophagosomes. Synthesized SM, Cer1P, and GSL are then delivered to the plasma membrane. Also 
shown is the turnover of SM via sphingomyelinases at the plasma membrane to Cer and downstream 
metabolites, So and S1P. Additionally, SM and GSL can be internalized through the endocytic 
pathway and trafficked to the lysosome where turnover takes place via the action of sphingomyelinase 
and ceramidase. Sphingosine (So) may then exit the lysosome and be recycled back into biosynthesis 
or phosphorylated and degraded. Also shown is the hypothesized hydrolysis of Cer to So within the 
autophagolysosome. This figure was adapted from [1, 35].  
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1.3  Signaling: Focus on Autophagic Pathway 
 SL such as So, Cer, S1P, and Cer1P are well documented to serve as important 
bioactive molecules involved in numerous cellular processes including, among others, 
growth, differentiation, inflammation, and apoptosis [1, 36].  These SL molecules directly 
regulate several downstream targets, which mediate their affects on cellular functions [1, 
36]. For example, So has been found to induce apoptosis [46] and prevent the phorbol-
ester dependent differentiation of promyelocytic leukemia cells (HL-60) [47], as well as 
inhibit cellular growth through cell cycle arrest in lymphoblastic leukaemic cells (Molt-4) 
[48]. These effects are, at least in part, modulated by the So-induced inhibition of protein 
kinase C (PKC) [49]. Additionally, Cer is known to be involved in the regulation of 
numerous apoptotic signaling pathways through the activation of its direct targets 
including, phosphoprotein phosphatases 1 and 2A [1, 50-54], many members of the PKC 
family [1, 55-57], and cathepsin D [1, 58, 59]. In contrast to the effects of So and Cer on 
cell growth and survival, S1P promotes proliferation and inhibits apoptosis with the 
delicate balance between these opposing molecules (So and Cer vs S1P) thought to be an 
important determinant of cell fate [60].  Furthermore, the phosphorylation of Cer to 
produce Cer1P has been associated with DNA synthesis [61], inhibition of apoptosis [62], 
and activation of cytosolic phospholipase A(2) (cPLA2) and the production of 
eicosanoids in response to inflammatory agonists [63].  In addition to the effects of these 
SL on the cellular functions discussed above, several of the aforementioned SL, including 
Cer and S1P, as well as a previously unrecognized bioactive SL, DHCer, have also been 
found to mediate an essential cellular process known as autophagy, which contributes to 
both normal cell functioning as well as disease [1, 35, 60].    
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1.3.1  Autophagic Process 
 Translated from Greek meaning “to eat oneself”, autophagy is an intracellular 
degradation and recycling pathway mechanism that is, in various forms, ubiquitous in 
eukaryotic cells, from yeast to mammals [64-66]. Indeed, genetic studies in yeast have 
identified many autophagy-related (ATG) genes essential for autophagy that are highly 
conserved across eukaryotes [67]. Conceptually, autophagy can be thought of as a seven-
step process that involves (1) induction, (2) nucleation,  (3) expansion, (4) completion, 
(5) fusion, (6) degradation, and (7) export (Fig. 1.4) [64-67].  
 Under normal conditions, a basal level of autophagy occurs as a housekeeping 
function in order to eliminate damaged or aged organelle and proteins [67]. However, 
cellular stresses such as nutrient starvation, pathogen infection, various drug treatments, 
and other environmental factors can induce a more dramatic autophagic response [67]. 
The induction of autophagy, in many cellular settings, is regulated by a serine/threonine 
kinase, mammalian target of rapamycin (mTOR) (Fig. 1.4), whose activity is inversely 
correlated with autophagy induction [68-71]. The mechanism by which mTOR interferes 
with autophagy induction in mammalian cells is currently unknown [68-71]. However, in 
yeast, mTOR affects autophagy by modulating the phosphorylation status of ATG protein 
13 (Atg13) (Fig. 1.4) [68-71]. Activated mTOR phosphorylates Atg13 at multiple sites 
reducing its affinity for ATG protein 1 (Atg1), an evolutionarily conserved 
serine/threonine kinase required for autophagosome formation [68-71]. Atg1 associates 
with several autophagy proteins in addition to Atg13, including Atg17, Atg29, and Atg31 
[68-71]. However, the interaction with Atg13 is required for Atg1 kinase activity [68-71]. 
Thus, activation of mTOR results in the suppression of autophagy [68-71]. In contrast, 
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the inhibition of mTOR represses Atg13 phosphorylation and the hypo-phosphorylated 
Atg13 associates with Atg1 promoting kinase activity and autophagy induction [68-71].  
Recently, a mammalian ortholog of Atg1, which is required for autophagosome 
formation in both Hek293 and HeLa cell lines, has been identified, ULK (UNC-51-like 
kinase); however, the mammalian ortholog of yeast Atg13, Atg17, Atg29, and Atg31 
have yet to be identified limiting the complete understanding of autophagy induction in 
mammalian systems and how the regulation of these processes couple with activation of 
vesicle nucleation and expansion (discussed below) [68-71].    
 During autophagic vesicle nucleation and expansion, proteins and/or organelles to 
be degraded are sequestered into double membrane intermediate vesicles known as 
autophagosomes [67]. Although the exact origin of the membrane of the mammalian 
autophagosome is controversial, studies have found that it is likely derived from a lipid 
bilayer formed from the ER and/or the trans Golgi network; however, de novo membrane 
formation from cytosolic lipids can not be excluded [72, 73]. The mechanisms of 
nucleation and expansion, which are still in the infancy of understanding, depend on the 
step-wise recruitment of specific ATG proteins, including two ubiquitin-like conjugation 
systems (Fig. 1.4) [67]. The initial step of vesicle nucleation involves the activation of 
Vps34, a mammalian phosphatidlyinositol 3-kinase, to generate phosphatidlyinositol-3-
phosphate, which is essential for elongation and recruitment of Atg proteins to the 
membrane [72, 74]. Activation of Vps34 catalytic activity occurs via its association with 
Atg6/Beclin1 in a multiprotein complex [72, 74].  The mechanism by which this complex 
promotes autophagy has yet to be determined; however, the interaction between Beclin1 
and Vps34 is essential for Vps34 kinase activity and thus vesicle nucleation [69, 70, 74]. 
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Beclin1 binding partners associated with the complex have been found to influence the 
activation of Vps34 [69, 70, 74]. For example, the association of UV irradiation 
resistance-associated tumor suppressor gene (UVRAG) with the complex has been found 
to promote Vps34 kinase activity and positively regulate autophagy; whereas association 
of the anti-apoptotic Bcl-2 protein has been found to inhibit Vps34 kinase activity and 
negatively regulate autophagy [69, 70, 74-76].  As described by Liang and co-workers, 
these two binding proteins represent the so-called “Yin-Yang” regulatory mechanism, 
which keeps autophagy within a normal range at the basal level [75]. However, following 
the addition of cellular stressors, such as those described above, Bcl-2 dissociates from 
the complex, whereas UVRAG remains disrupting the homeostatic balance and 
promoting increased autophagy [75, 76].  
 Elongation of the nascent autophagosomal membrane requires two ubiquitin-like 
conjugation systems (Fig. 1.4) [72, 74]. In the first, Atg12 is complexed to Atg5 in an 
ATP-dependent manner with Atg7 acting as an E1 activating enzyme and Atg10 acting as 
an E2 carrier protein [72, 74]. The Atg12-Atg5 complex then pairs with Atg16 dimers to 
form a multimeric complex, which is thought to induce curvature in the growing 
membrane through asymmetric recruitment of LC3-II (discussed below) [72, 74]. Once 
autophagosome formation is complete, the Atg12-Atg5-Atg16 multimer dissociates from 
the membrane [72, 74]. The second ubiquitin-like system facilitates the conjugation of 
phosphatidylethanolamine with Atg8 mammalian homologue, microtubule-associated 
protein 1 light chain 3 (LC3) [72, 74]. Following synthesis, nascent LC3 is cleaved by a 
protease, Atg4, exposing a glycine residue at its C-terminus and forming a species known 
as LC3-I [72, 74]. The carboxyterminal glycine is then activated in an ATP-dependent 
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manner by E1-like Atg7, transferred to E2-like Atg3 and conjugated to 
phosphatidylethanolamine becoming the LC3-II species [72, 74]. While LC3-I displays a 
cytosolic localization, LC3-II associates with both the outer and inner portions of the 
autophagosomal membrane, where it is thought to play a role in the hemifusion of 
membranes [72, 74].  
 The autophagosome is completed following the fusion of the two membrane 
extremities [67]. The completed autophagosome then fuses with the lysosome to form the 
autophagolysosome, where the sequestered proteins and/or organelle are degraded by 
lysosomal hydrolases in a process requiring cathepsins B and D [72].  Finally, the 



































































Figure 1.4 The Autophagic Process Following induction, autophagy begins with the nucleation of 
the isolation membrane, which engulfs cytosolic proteins and/or organelle to be degraded. LC3 is 
recruited to the isolation membrane, where it facilitates membrane elongation and closure to form the 
autophagosome. Upon completion, the autophagosome fuses with the lysosome and the LC3 on the 
outer portion of the autophagosomal membrane is recycled. Finally, the LC3 on the inner portion of 
the autophagolysosomal membrane and the engulfed proteins/organelle are degraded by lysosomal 
proteases and the resulting macromolecules are exported for continued cell maintenance. Also shown 
is the control of induction by mTor, as well as vesicle nucleation and membrane expansion/completion 
by the Vps34/Beclin-1 protein complex and Atg12-Atg5 and LC3 conjugation systems, respectively, 
as described in the text. This figure was adapted from [67, 68, 71].  
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1.3.2  Methods for Monitoring Autophagy 
 Studies of autophagy frequently use cells that stably or transiently express a 
green-fluorescent-protein (GFP)-tagged LC3 protein (GFP-LC3) [77-80], as depicted in 
Figure 1.4. Because LC3-I displays a cytosolic localization and LC3-II associates with 
both the outer and inner portions of the autophagosome, the activation of autophagy 
within cells stably or transiently expressing GFP-LC3 results in the appearance of LC3-II 
puncta [80]. Following fusion with the lysosome, the LC3-II on the outer portion of the 
membrane is recycled, and the LC3-II on the inner portion of the membrane is degraded 
with the sequestered proteins and/or organelle [80]. Therefore, GFP-LC3 is either 
visualized by fluorescence microscopy as diffuse throughout the cytosol or as discreet 
punctate vesicles representing autophagosomes and/or autophagolysosomes [79, 80].  
It is worth noting that the use of transiently transfected cells is not recommended 
for assays of autophagy due to the aggregate prone nature of the GFP-LC3 protein when 
transiently overexpressed [79-81]. This pitfall may be avoided through the use of stable 
transfectants with a selection of clones that express appropriate levels of GFP-LC3 
without non-specific aggregation [79-81]. Additionally, transfection reagent itself has 
been found to be a potent inducer of autophagy resulting in the possibility of a potentially 
false interpretation of autophagy induction when transfection reagent is used during 
experimental conditions and further emphasizing the importance of using GFP-LC3 
stable transformants for autophagy analysis [82].  
Quantitative analysis of GFP-LC3 puncta, and thus autophagic induction, is 
reported as the number of GFP-LC3 puncta/cell or as the percentage of cells with GFP-
LC3 associated autophagosomes [79, 80]. In order to remove subjectivity and provide 
 16 
consistency between independent experiments, a uniform method must be defined for 
determining ‘puncta’ regardless of the reporting method [79, 80]. This can be achieved 
through the use of software such as ImageJ, which allows the user to define both the 
fluorescence threshold, as well as the size threshold of the desired ‘puncta’. Additionally, 
if the results are reported as the percentage of cells with GFP-LC3 autophagosomes, a 
third threshold should be established in order to distinguish ‘autophagy active’ cells since 
low numbers of puncta may be observed even under basal conditions due to the 
housekeeping functions of autophagy [79, 80].  
In addition to fluorescence microscopy, biochemical assays can also be used to 
monitor autophagy. The conversion of LC3-I to LC3-II can be followed via SDS-PAGE 
and Western blotting [79, 80, 83]. Interestingly, although the molecular weight of LC3-II 
is greater than that of LC3-I, LC3-II experiences an increased mobility and migrates 
faster than LC3-I in SDS-PAGE [79, 80, 83]. This is thought to be due to the extreme 
hydrophobicity of LC3-II following its conjugation with phosphatidylethanolamine [79, 
80, 83]. It is important to note that the conversion of LC3-I to LC3-II is a measure of 
phosphatidylethanolamine conjugation and not processing, as would be predicted by the 
apparent size reduction when monitoring SDS-PAGE [79, 80, 83].  LC3-I has a 
molecular mass around 16 kDa, and LC3-II is usually detected around a molecular mass 
of 14 kDa [79, 80, 83]. The amount of LC3-II correlates with autophagosome formation, 
and thus, it can be used as an indicator of autophagy induction [79, 80, 83].  
Finally, in some cases, the induction of autophagy is accompanied by an increase 
in the mRNA expression of some of the aforementioned ATG genes, such as Atg8/LC3 
and Atg12 [79, 84, 85]. Although, it is not currently clear whether increases in mRNA are 
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sufficient to induce autophagy, mRNA measurements may provide correlative data to 
support the other assay methods described above [79]. 
1.3.3  Autophagy: Relevance to Disease 
 Although the primary function of autophagy is to aid in the adaptation of cellular 
stress by enabling cells under adverse conditions to degrade cytosolic proteins and 
organelles in order to generate a supply of essential nutrients, autophagy has also been 
implicated in the pathogenesis of many diseases, including cancer [67, 86]. And more 
recently, autophagy has been identified as a component of innate immunity where it is 
involved in host defense and elimination of intracellular bacterial pathogens [67, 87-89].  
 Although the immune system is usually successful in eliminating pathogenic 
organisms, which target macrophages or epithelial cells and enter these cells via 
phagocytosis or by facilitating their own uptake [67]. Some pathogenic organisms 
effectively combat cellular defenses once inside the cell, and escape into the cytosol or 
modify the phagosome in order to establish a replicative niche within this vesicle [67, 
89]. In these cases, a second line of defense may be activated -- autophagy -- in order to 
effectively eliminate these organisms. For example, L. monocyogenes, a virulent 
foodborne pathogen, readily escapes the phagosome following cellular entry, thrives on 
cytosolic nutrients, and begins to replicate within the host cell [89, 90]. Treatment of L. 
monocyogenes infected macrophages with the antibiotic chloramphenicol, which induces 
the expression of autophagy gene Atg12 (discussed above) [91], sequesters the bacterium 
into double-membraned autophagosomes allowing for their removal from the cytosol and 
subsequent degradation within the autophagolysosome [90]. In addition to sequestering 
cytosolic bacterial pathogens, the induction of autophagy has also been shown to promote 
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the maturation of arrested phagosomes that have been transformed by certain pathogenic 
organisms into protective environments within the cell where they may survive and 
reproduce [67, 89]. M. tuberculosis, the causative agent of tuberculosis, readily persists 
and reproduces inside the phagosome ultimately forcing the lysis of the macrophage host 
cell and the release of mycobacteria into neighboring cells [67, 92]. Alternatively, the 
induction of autophagy in infected macrophages results in the fusion of the mycobacteria 
containing phagosomes with autophagosomes, degradation of the bacteria, and ultimately 
survival of the host cell [92]. Interestingly, the emergence of multi-drug resistant M. 
tuberculosis and other infectious strains are becoming a major health concern throughout 
the world [93]. With this in mind, the development of new therapeutic intervention 
strategies to supplement existing therapies is a high priority [93]. The research described 
herein [Chapter 2 and [45]] looks at the ability of an agent, which induces changes in SL 
metabolism, to be an effective inducer of autophagy in macrophage cells. Thus, paving 
the way for new therapeutic interventions that outsmart pathogens by modulation of 
autophagy through manipulation of the SL pathway.  
 Paradoxically, in addition to its role in cell survival, activation of autophagy can 
also be induced as part of a cell death response, and the accumulation of autophagosomes 
is characteristic of “type II” or  “autophagic” cell death [1, 67]. One example of the dual 
role of autophagy is evident in cancer therapy [70, 94]. In tumor cells, autophagy is often 
observed in response to chemotherapy and radiation where it sometimes functions as a 
survival pathway in order to generate a supply of essential nutrients and re-establish 
cellular homeostasis during times of metabolic stress, as a means to prevent apoptotic cell 
death [70]. In these cases, the inhibition of autophagy provides a means to sensitize tumor 
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cells to chemotherapeutic agents [70]. For example, treatment of the chronic myelogeous 
leukemia cell line, K562, with imatinib, a currently used chemotherapeutic that inhibits 
tyrosine kinase activity, activates autophagy as a survival mechanism in order to avoid or 
delay apoptotic cell death [70, 95]. However, the inhibition of autophagy, through the use 
of pharmacological agents or the downregulation of autophagy genes with siRNA, 
accelerated the cell death response suggesting that the combination of autophagy 
inhibitors with conventional chemotherapeutic drugs could be valuable in the treatment 
of chromic myelogenous leukemia [95].  
 Conversely, malignant cells often acquire genetic deletions or mutations that 
render them resistant to the classical apoptotic cell death induced by many anti-cancer 
therapies, which ultimately results in poor prognosis [69, 96]. In these cases, the use of 
autophagy inducing drugs offers an alternative way to induce cell death in apoptosis-
resistant tumors [69, 96].  One example of this principle involves treatment of MCF7 
breast cancer cells, which do not express caspase-3 [97-99], a cysteine protease that plays 
a central role in executing apoptosis [97], with 4-hydroxyphenylretinamide (fenretinide; 
4-HPR), a chemotherapeutic agent which has shown success in vitro, in animal 
experiments, and in select clinical trails [100]. The cytotoxic effects of 4-HPR, in many 
cancer lines, have been attributed to the induction of apoptosis and caspase activation 
[100].  However, treatment of apoptotic defective-MCF7 cells with 4-HPR, was found to 
result in cytotoxicity through the induction of autophagic cell death, as well [99]. This 
study supports the role of autophagy induction in the activation of an alternative cell 
death pathway in apoptotic defective cells as a means to increase cancer therapeutic 
efficacy [99]. This idea could prove to be particularly important in breast cancer, as a 
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recent study of malignant breast tissue samples revealed that 75% of the analyzed tissues 
were apoptotic defective lacking both transcription and expression of caspase-3 [96, 101].  
 Chapters 3 and 4 of this work explore the ability of the promising 
chemotherapeutic agent, 4-HPR, to alter SL metabolism and the role of SL biosynthesis 
in 4-HPR-induced autophagy and autophagic cell death.  Additionally, Chapter 4 
examines the ability of known modulators of SL biosynthesis to enhance 4-HPR-induced 
autophagic cell death, as a promising approach to improve cancer chemotherapy, 
particularly in apoptotic-defective breast cancer cells. 
1.3.4  Sphingolipids and Autophagy 
 Because of their involvement in membrane organization and structure, as well as 
their participation in cell survival and cell death signaling pathways (as briefly discussed 
above) it is easy to imagine that SL might be unique mediators of autophagy. Indeed, 
bioactive SL species, including Cer, S1P, and most recently DHCer have been shown 
mediate two autophagic pathways, described as protective autophagy and autophagic cell 
death, which display opposing functions on cell fate [1, 102-110].  
 Several studies have elegantly established the ability of exogenous Cer to mediate 
autophagy [1, 102, 104, 105]. In colon (HT-29), breast (MCF7), and cervical (HeLa) 
cancer cells, C2-Cer and/or C6-Cer treatment has been found to stimulate autophagy by 
inhibiting the mTOR signaling pathway [102], which plays a central role in autophagy 
induction (discussed above), as well as by upregulating the transcription and expression 
of Beclin1[102] and promoting the dissociation of the Beclin1/Bcl-2 complex [104], 
which is important for vesicle nucleation and expansion (discussed above). C2-Cer 
treatment has also been associated with the induction of autophagic cell death in 
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malignant glioma (U373-MG and T98G) through activation of BNIP3, a mitochondria-
associated protein that induces nonapoptotic cell death [105].  In addition to the induction 
of autophagy by short-chain Cer, current and potential anti-cancer agents, such as 
tamoxifen and ∆9-tetrahydrocannabinol (THC), respectively, have been shown to induce 
autophagic cell death by increasing endogenous Cer [102, 104, 106, 111]. For example, 
treatment of MCF7 and HeLa cells with tamoxifen mimicked the effects exogenous of 
Cer, promoting autophagosome formation through inhibition of the mTOR signaling 
pathway [102], up-regulation of Beclin1/Atg6 [102], and promotion of the dissociation of 
the Beclin1/Bcl-2 complex [104]. Interestingly, inhibition of de novo Cer biosynthesis 
with the SPT inhibitior, myriocin/ISP1, prevented the tamoxifen-induced accumulation of 
autophagic vesicles [102, 104] suggesting that Cer made via the de novo biosynthetic 
pathway is an important mediator of autophagic cell death following treatment with this 
chemotherapeutic agent. Additionally, increases in de novo Cer production upstream of 
mTOR inhibition implicate this bioactive SL species in the THC-induced autophagic cell 
death of glioblastoma (U87MG) cells [106].  
 Whereas Cer-induced autophagy has been associated with autophagic cell death, 
increases in endogenous S1P have been found to induce survival-mediated or protective 
autophagy in MCF7 breast cancer cells during times of nutrient starvation [103, 112]. 
Inhibition of SphK with siRNA suppressed autophagy and increased cell death following 
starvation [103, 112]. Distinct from Cer-induced autophagy, S1P-induced autophagy acts 
independently of an increase in Beclin1 expression; however, inhibition of the mTOR-
signaling pathway was observed [103, 112]. Interestingly, S1P-mediated autophagy was 
not inhibited by fumonisin B1 (FB1), an inhibitor of CerS, indicating that its mechanism 
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is not dependent on Cer formation [103]. Consistent with the Cer-independent effect, 
inhibition of sphingosine-1-phosphate phosphohydrolase-1 (SPP1), the enzyme that 
dephosphorylates S1P and Sa1P in the ER, was found to induce autophagy in the absence 
of alterations to Cer or DHCer species; whereas, S1P and Sa1P were significantly 
increased [107].  Furthermore, pharmacological inhibition of SphK with 3-(4-
chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (ABC294640) 
induces autophagic cell death in various carcinoma cell lines [108], which is likely due to 
the inhibition of S1P induced protective autophagy and/or an accumulation of Cer.  
 In addition to the above investigations, DHCer has been most recently identified 
as a third SL-mediator of autophagy [1, 109, 110]. The ability of exogenously added 
DHCer to activate autophagy, as well as the ability of the anti-cancer agent 4-HPR to 
induce autophagy through increases in endogenous DHCer was first documented in the 
DU145 prostate cancer cell line [1], and these findings are extended to the Hek293 and 
MCF7 cell lines in Chapter 3 and Chapter 4 of this work, respectively. These studies 
were quite surprising, as DHCer has long been regarded as an innocuous molecule due to 
its inability to activate in vitro targets of Cer or affect Cer-mediated signaling pathways 
[1]. Recent studies have provided additional support for this finding and demonstrated the 
ability of exogenous increases in DHCer, via inhibition of DES, to induce both protective 
autophagy and autophagic cell death [109, 110]. For example, treatment of gastic cancer 
cells (HGC-27) with resveratrol is accompanied by a robust accumulation of autophagic 
vesicles in the absence of cellular toxicity [109]; while, treatment of prostate cancer cells 
(PC-3 and LNCaP) with gamma-tocotrienol resulted in autophagic cell death, which 
could be inhibited by ISP1 [110]. The idea that DHCer (and possibly other DHSL) 
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accumulation influences both protective autophagy and autophagic cell death is also 
apparent in Chapter 3 of this work, through a comparison of the cellular effects of 4-HPR 
and a novel DES inhibitor, 4-hydroxypalmitanilide (4-HPA). Intriguingly, none of the 
reported Cer-mediated autophagic pathways (discussed above) can be induced by both 
Cer and DHCer [102]; therefore, it is likely that novel signaling pathways and targets are 
responsible for this previously uncharacterized signaling function of DHCer and 
determine its effect on cell fate.  
 The studies described above provide evidence that bioactive SL have emerged as 
important effectors in regulating the autophagic pathway, as well as determining the 
associated cellular consequence, suggesting that SL might play a role in many, if not all 
forms, of autophagy. Thus the studies described herein provide further insight into the 
ability of bioactive molecules to influence SL metabolism and the ability of SL to 
regulate/induce autophagy in diverse cellular situations which could lead to novel 
strategies for manipulating autophagy in infection, cancer, and other disease.   
1.4  Objective(s) 
 The over-arching objective of this study is to understand how two agents 
associated with infection and cancer treatment, Kdo2-Lipid A (KLA) and 4-HPR, 
respectively, affect SL metabolism and the regulation of the autophagic pathway, through 
the use of lipidomic technologies, genomic analysis, and cellular biology techniques. 
Chapter 2 focuses on the ability of a TLR4 specific lipopolysaccharide (LPS), KLA, to 
induce changes in SL metabolism and to activate the autophagic pathway in RAW264.7 
macrophage cells. In Chapter 3, the focus shifts to an analysis of the structural features 4-
HPR that modulate SL metabolism, induction of autophagy, and sometimes cell death. 
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Chapter 4 examines the role of SL in 4-HPR-induced autophagic cell death in MCF7 
breast cancer cells, as well as determines if autophagic cell death/cytoxicity can be 
enhanced through concurrent treatment with 4-HPR and other known modulators of SL 
biosynthesis. It is hoped that a better understanding of the inter-relationship between SL 
metabolism and autophagy will lead to new strategies for manipulating this process in 
infection, cancer, and other diseases.   
 
 





KDO2-LIPID A, A TLR4 SPECIFIC AGONIST, INDUCES DE NOVO 
SPHINGOLIPID BIOSYNTHESIS, WHICH IS ESSENTIAL FOR 
THE INDUCTION OF AUTOPHAGY  
2.1  Introduction 
 SL are a complex family of molecules [2] that participate in many facets of cell 
structure and function [35, 60].  For some categories of cells, such as macrophages, 
normal and abnormal functions have been associated with seemingly every SL 
subcategory, including So [113], S1P [114], Cer [115], Cer1P [116], SM [117], and both 
simple (e.g., GlcCer) [118] and more complex GSL [119-121].  Likewise, macrophage 
behavior can be modified by inhibition of de novo SL biosynthesis by L-cycloserine 
[122] and myriocin [123], and by SL analogs such as FTY720 [124], PCERA-1 (a Cer1P 
analog) [125], and α-galactosylceramide (α-GalCer) [126], inter alia.   
 As part of the characterization of the mouse macrophage lipidome by the LIPID 
MAPS Consortium (www.lipidmaps.org), the major SL subspecies of the mouse 
macrophage-like cell line, RAW264.7, have been quantified from the first detectable 
biosynthetic intermediate (Sa) through the branchpoint where Cer is partitioned into SM, 
Cer1P, GlcCer, and GalCer using liquid chromatography, electrospray ionization-tandem 
mass spectrometry (LC ESI-MS/MS) [127].  The Consortium has also investigated the 
effects of activation of these cells with KLA, a chemically defined substructure of 
bacterial LPS that is specifically recognized by the TLR4 receptor [128].  LPS has been 
previously reported to stimulate SL biosynthesis in liver [129] and extrahepatic tissues 
[130], and to elevate Cer in RAW264.7 cells by induction of turnover of pre-existing SL 
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[131].  Our studies have found that KLA nearly doubles the SL content of RAW264.7 
cells, with increases in many of the SL subspecies summarized in the pathway scheme 
shown in Fig. 2.1.  This report notes that two of the reasons that stimulated RAW264.7 
cells have more SL are that KLA increases de novo biosynthesis but inhibits cell division, 
therefore, the size of the cells increases and they contain large numbers of intracellular 
vacuoles (autophagosomes).  Induction of autophagy has previously been noted upon 
TLR4-activation and is thought to be important in phagocytosis and regulation of the 
inflammatory response [87, 132, 133].  This study has additionally established that de 
novo SL biosynthesis is required for autophagy, and that Cer are associated with 
autophagosomes, implying that they play structural and/or signaling roles in this 
important biochemical process. 
2.2  Experimental Procedures 
2.2.1 Materials 
 The suppliers for the reagents were: Kdo2-Lipid A and the internal standard 
cocktail for SL analysis by LC ESI-MS/MS (Ceramide/Sphingoid Internal Standard 
Mixture II, LM-6005) (Avanti Polar Lipids, Alabaster, AL); [U-13C] palmitic acid (98%) 
(Cambridge Isotopes, Andover, MA); fatty acid-free BSA (Calbiochem, La Jolla, CA); 
Hoechst 33342 (Invitrogen, Carlsbad, CA); myriocin/ISP1 (Biomol, Plymouth Meeting, 
PA); the mouse monoclonal antibody to SPT1 (anti-LCB1), anti-BiP/GRP78 and anti-
GM130 (BD Biosciences, San Jose, CA); rabbit monoclonal anti-HA-tag and rabbit 
polyclonal LC3B antibody (Cell Signaling Technology, Boston, MA); mouse monoclonal 
anti-Cer antibody clone 15B4 (Alexis Biochemicals, San Diego, CA) This antibody clone 
has been successfully used in immunocytochemistry applications with no indication of 
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nonspecific reactions with other lipids [134-139]. The secondary Alexa Fluor-conjugated 
F(ab)2 fragment goat anti-mouse antibody and goat anti-rabbit antibody were from 
Molecular Probes, Inc. (Eugene, OR.).  The sources for liquid chromatography columns, 
solvents, and other reagents used for mass spectrometry were the same as in the 
published method [127]. 
2.2.2 Cells and Cell Culture 
 RAW264.7 cells were obtained from the American Type Culture Collection 
(Manassas, VA) and grown in DMEM (MediaTech, Manassas VA) supplemented with 
10% heat-inactivated fetal calf serum (HyClone Logan, UT) and penicillin (100 U/mL) 
plus streptomycin (0.1mg/mL). The cells were maintained in a 37°C, 90% relative 
humidity, 5% CO2 environment. All cell culture conditions, unless otherwise noted, 
followed the standard protocol adopted by the LIPID MAPS Consortium 
(www.lipidmaps.org): Warm the growth medium for 15 – 20 minutes in a 37°C water 
bath. After warming, place a volume of the warmed fresh medium into new vessels. (See 
below for plate size, cell density, and medium volume recommendations). To begin 
subculturing, aspirate the old medium from the cells and rinse them once with DPBS. 
Add fresh medium (~10 ml to 100 mm dish) to the cells and gently scrape the cells until 
all are dislodged. Pipette the cell suspension, with a 10 ml pipette, up and down five 
times, without introducing bubbles. Count the cells using a hemacytometer and dispense 
the cells into the new vessels growing the cells to no more than 80% confluence, (~2-3 
days) before passing or harvesting. Recommended cell seeding and media volume for 
specific plate formats to obtain approximately 80% confluence in 2-3 days: 150 mm 
plates: 5 x 106/20 ml medium, 100 mm plates: 2 x 106/10 ml medium, 60 mm plates: 5 x 
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105/5 ml medium, 6-well plates: 3 x 105/well/3 ml medium, 12-well plates: 7.5 x 
104/well/2 ml medium, 24-well plates: 5 x 104/well/1 ml medium, 96-well plates: 2 x 
104/well/100 µl medium 
2.2.3 Lipid Extraction and Analysis by LC-ESI MS/MS 
 The extraction and analysis method has been thoroughly described [127, 140]. 
The mass spectrometry data were collected using a PE Sciex API 3000 triple quadrupole 
and a 4000 quadrupole linear-ion trap mass spectrometer. For quantification, the samples 
were spiked with the internal standard cocktail (Avanti Polar Lipids, Alabaster, AL).  
DNA was quantified using the Quant-iT DNA Assay Kit, Broad Range (Molecular 
Probes), and the relationship 3 µg of DNA = 1 x 106 RAW264.7 cells, was empirically 
determined by comparison of DNA amount and number of cells counted using a 
hemocytometer. 
2.2.4 Stable Isotope Labeling of Sphingolipids 
 Uniformly labeled 13C-palmitate was mixed with fatty acid-free bovine serum 
albumin (BSA) at a 1:1 molar ratio to make a 1 mM solution1, which was diluted to 0.1 
mM with complete cell culture medium, and filter sterilized just before use. The [U-13C]-
palmitate/BSA was added to cells at the same time as the KLA or vehicle, incubated for 
up to 24 h, then the cells were extracted for lipid analysis as described previously [127, 
140].  To quantitate the three categories of SL labeled with [U-13C]-palmitate (i.e., in the 
sphingoid base backbone alone—which we designate “Base-labeled”—in the fatty acid 
                                                
 
 
1 Solutions containing BSA were tested for endotoxin contamination because we noted that fatty acid-free 
BSA from some suppliers was contaminated or became so during incubation at 37oC for the preparation of 
the fatty acid-BSA complex. 
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only—“Fatty acid-labeled”—and both the sphingoid base and fatty acid—“Dual-
labeled”), the additional multiple reaction monitoring (MRM) pairs were added:  the [M 
+ 16] precursor ions and [M + 16] product ions for Base-labeled; [M + 16] precursor ions 
and [M + 0] product ions for “Fatty acid-labeled”; and [M + 32] precursor ions and [M + 
16] product ions for “Dual-labeled.” The MRM extracted ion chromatogram peak areas 
of all four SL isotopomers were integrated (Analyst 1.4), converted to picomoles using 
the peak areas of the internal standards, and normalized to the micrograms of DNA in the 
sample, except where otherwise noted. 
2.2.5 Confocal Immunofluorescence Microscopy 
 RAW264.7 cells stably expressing GFP-LC3 were cultured on glass coverslips 
(VWR, Inc. West Chester, PA) in 24-well plates. Following treatment, cells were fixed 
with 4% formaldehyde for 15 minutes.  Fixed cells were rinsed in PBS, and the nucleic 
acids were stained by incubating fixed cells with 1 µg/mL Hoechst 3342 for 7 min at 
room temperature.  Stained cells were rinsed in PBS and mounted in Fluoromount G 
(Southern Biotechnology Associates, Inc., Birmingham, AL) prior to observation under a 
Zeiss LSM 510 inverted laser scanning confocal microscope (Heidelberg, Germany).  
Images were collected with the resident Zeiss confocal microscope software and analyzed 
using ImageJ version 1.41a (National Institute of Health). The ImageJ plug-in Analyze 
Particles was used to identify “autophagosomes” as defined by a threshold value of 159-
255 [141] and a particle size of 0.07 to 7 µm2 [142]. Statistical analysis was performed 
using a two-tailed Student’s t-test. 
2.2.6 Generation of RAW264.7 Cells Stably Expressing GFP-LC3 
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 LC3A cDNA was obtained from Origene. To generate N-terminal GFP-tagged 
LC3, the LC3A gene was amplified using the following gene-specific primers: 5'-
ATGCCCTCAGACCGGCCTTT-3' and 5'-GAAGCCGAAGGTTTCCTGGGAGG-3'. 
The PCR fragment corresponding to the coding sequence of LC3A was then cloned into 
pEGFP-C2/SmaI (Clonetech, Mountain View, CA) resulting pEGFP-C2-LC3A. 
Sequencing was used to confirm the fidelity of the construct.  
RAW264.7 cells stably expressing GFP-LC3 were generated by transfection with 
pEFGP-C2-LC3A.  Transfection was performed in 100-mm dishes (3.0 x 106 cells/dish) 
with 6 µg plasmid DNA/plate with GeneJuice® (Novagen; EMD Biosciences, San 
Diego, CA) according to the manufacturer’s protocol.  Following 48 h of exposure, cells 
were washed with PBS and selected in media containing 300 µg/mL of G418 (Sigma-
Aldrich) for 14 days.  The media was changed every other day. After two weeks, selected 
G418-resistant colonies were cloned by two rounds of limiting dilution in a 96 well plate 
order to establish fluorescent colonies originating from a single cell. In order to confirm 
localization and expression of the LC3, GFP-LC3-transfected RAW264.7 cells were 
cultured on 12 mm cover slips (VWR; West Chester, PA). Following exposure to Kdo2-
Lipid A (Avanti Polar Lipids; Alabaster, AL) for 24 h, cells were fixed in 4% 
formaldehyde and analyzed by fluorescence confocal microscopy. 
2.2.7 Immunohistochemical Analysis of the ER and Golgi 
 For visualization of the ER and Golgi, fixed cells were permeabilized with 0.2% 
Triton X-100 for 5 min, blocked in 3% BSA, 2% serum in PBS for 2 h, and subjected to 
indirect immunofluorescence staining. Cells were incubated overnight at 4 °C with anti-
BiP (1:500) for visualization of the ER or anti-GM130 (1:500) for visualization of the 
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Golgi diluted in 0.1% BSA in PBS. The cells were washed three times with PBS and 
incubated with the Alexa Fluor-conjugated secondary antibody (1:200) diluted in 0.1% 
BSA in PBS for 3 h at room temperature prior to nucleic acid staining.  
2.2.8 Immunohistochemical Analysis of Ceramide Localization 
 Cer staining was performed through the adaptation of [134]. Briefly, for surface 
Cer staining, the non-specific binding sites of fixed cells were saturated for 2 h at room 
temperature with 3% BSA, 2% serum in PBS followed by overnight incubation at 4°C 
with anti-Cer Ab (1:50) diluted in 0.1% BSA. In order to visualize intracellular Cer, the 
staining protocol was continued with a second fixation with 4% formaldehyde for 20 min 
at room temperature. The cells were then washed twice with PBS and permeabilized with 
0.2% Triton X-100 for 5 min. Non-specific intracellular binding sites were blocked with 
3% BSA, 2% serum in PBS for 45 min followed by overnight incubation at 4°C with 
anti-Cer Ab (1:50) diluted in 0.1% BSA.  The cells were then washed three times and 
incubated with the Alexa Fluor-conjugated secondary antibody (1:200) diluted in 0.1% 
BSA for 3 h at room temperature prior to nucleic acid staining. 
2.2.9 Measurement of Cell Diameter and Area 
 RAW264.7 cells were cultured on glass coverslips (VWR, Inc. West Chester, PA) 
in a 24-well plate. Following treatment, cells were fixed with 4% formaldehyde in PBS at 
room temperature for 15 min.  Fixed cells were rinsed in PBS and mounted in 
Fluoromount G (Southern Biotechnology Associates, Inc., Birmingham, AL) prior to 
observation under a Zeiss LSM 510 inverted laser scanning confocal microscope 
(Heidelberg, Germany).  Bright field images were collected with the resident Zeiss 
confocal microscope software and cellular diameter measured using ImageJ version 1.41a 
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(National Institute of Health).  The surface area was calculated using the measured 
diameter. 
2.2.10 Analysis of Autophagy in CHO-LYB and CHO-LYB-LCB1 Cells 
 Cells were obtained from Professor Kentaro Hanada at the National Institute of 
Infectious Diseases in Tokoyo, Japan and verified to have the phenotype of being 
defective in de novo SL biosynthesis due to mutation of SPT1 (CHO-LYB) [143]. This 
pathway is restored in the CHO-LYB-LCB1 cell line by stable transfection with wild-
type SPT1 [143].  In order to monitor autophagy, CHO-LYB and CHO-LYB-LCB1 cells 
were transfected with GFP-LC3. Transient transfection was performed using GeneJuice® 
transfection reagent (Novagen; EMB Biosciences, San Diego, CA) according to 
manufacturer’s protocol. 24 h after transfection, cells were treated with vehicle control 
(EtOH) or 4-HPR (10 µM). 4-HPR is an established inducer of autophagy in a variety of 
cell lines [1, 99, 144]. Following 24 h treatment, cells were fixed with 4% formaldehyde 
in PBS at room temperature for 15 minutes.  Fixed cells were rinsed in PBS and mounted 
in Fluoromount G (Southern Biotechnology Associates, Inc., Birmingham, AL) prior to 
observation under a Zeiss LSM 510 inverted laser scanning confocal microscope 
(Heidelberg, Germany). Autophagic cells were identified as cells with five or more GFP-
LC3 punctate autophagosomes for each condition. 
2.3  Results 
 Figure 2.1 depicts the early steps of SL biosynthesis with the average number of 
molecules per cell for each subspecies that has been quantified in RAW264.7 cells with 
and without KLA-activation.  These averages have been calculated using the 24 h data 
from the LIPID MAPS time course studies and information about the reproducibility of 
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replicates, other time points, etc. can be obtained from the web site www.lipidmaps.org.  
The sum of all of these SL in RAW264.7 cells without KLA stimulation is ~1.5 x 109 
molecules/cell (in other units: 0.82 nmol/µg DNA, 2.4 nmol/106 cells), which is a slight 
underestimation of the total SL content because it does not include small amounts of 
more complex GSL.  For comparison, the sum of all of the lipids in RAW264.7 cells is 
6.2 x 109 molecules per cell (3.4 nmol/µg DNA, 10.3 nmol/106 cells) (calculated from the 
data on www.lipidmaps.org, exempting triacylglycerols, cholesterol esters and 
diacylglycerols because they are likely to be found mostly in lipid droplets).  Therefore, 
SL constitute approximately one fourth of the membrane lipid of these cells. 
 It is noteworthy that SM (1,200 x 106 molecules) and dihydroSM (DHSM) (240 x 
106 molecules) account for a large fraction of this total (Fig. 2.1, upper numbers).  In 
contrast, 3-KSa, the first intermediate of de novo SL biosynthesis, is too low to detect, 
which is consistent with previous estimates that it is rapidly reduced to Sa [14, 145].   
Other intermediates of SL biosynthesis and turnover are present in more substantial 
amounts; for example, each RAW264.7 cell has, on average, 0.9 x 106 molecules of Sa, 
20 x 106 molecules of DHCer, 41 x 106 molecules of Cer, and 9.5 x 106 molecules of So.  
In contrast, the amounts of Sa1P and S1P are very low (0.02 and 0.07 x 106 molecules), 
and Cer1P is intermediate (0.4 x 106 molecules).  GlcCer is relatively prevalent (52.5 x 





Figure 2.1 KLA Induces Substantial Increases in the Amounts of Multiple Cellular 
Sphingolipids RAW264.7 cells were incubated with vehicle control (PBS) or KLA (100 ng/mL). 
Following 24 h of treatment, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. 
The number of million molecules per cell for each sphingolipid species is shown for control (upper 
number) and KLA (lower number) treated cells with heat map coloration to illustrate the fold change 
of each subspecies. Data represent the mean (n=9).   
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2.3.1  KLA Induces Substantial Increases in the Amounts of Multiple Cellular 
Sphingolipids2 
 After 24 h of stimulation with KLA (Fig. 2.1, the lower numbers), almost every 
SL subspecies was higher than in the control, with about half increasing by > 1.5-fold, as 
depicted by a heat map-style coloration of the borders (red reflecting increases).  The SL 
sum increased to 2.7 x 109 molecules per cell (1.8-fold) at this time point.  Interestingly, 
total lipids also increased 1.8 fold, from 6.2 to 10.9 x 109 molecules/cell (data not 
shown). This fold increase was calculated by the summation of all lipid species measured 
by the LIPID MAPS consortium (www.lipidmaps.org)3. 
 The time course changes for each subspecies of DHCer and Cer are shown in Fig. 
2.2, with sums for all the chain lengths in Fig. 2.2B and D.  Significant differences in 
total DHCer and Cer for the KLA-treated and control cells were found 12 h after KLA 
addition, and both were ~5-fold higher for the KLA-treated cells at 24 h (Fig. 2.2B and 
D). It is interesting that control cells displayed a decrease in total DHCer and Cer over 
the time course. Although the reason for this decrease is unclear, it is expected to be the 
result of continued growth resulting in increases in cell density similar to decreases 
cholesterol metabolism as cells reach confluency [146]. This decrease in control cell 
lipids has also been found in other lipid categories, analyzed by the LIPID MAPS 
Consortium, such as certain species of fatty acids, glycerophospholipids, and sterol lipids.   
                                                
 
 
2  The KLA time course data (sphingolipid amounts as pmol/µg DNA and microarray data) described in 
this section are also shown on the LIPID MAPS website (www.lipidmaps.org) as required by the NIH as 
part of the data sharing requirement for this Consortium.  
3 This calculation does not include measured quantities of triglycerides or cholesteryl esters since a 
substantial portion is likely to be stored in cytoplasmic lipid droplets rather than cell membranes per se 
[122]. 
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 Elevations in the C16- subspecies of DHCer and Cer were evident at 8 h (Fig. 
2.2A & C), and these subspecies were also the highest at 24 h (Fig. 2.2A & C and Fig. 
2.3).  A similar time course profile (i.e., with at least the C16-subspecies being elevated 
at 8 h) was seen for SM (Fig. 2.4A), MH-Cer (i.e., GlcCer and GalCer, which were 
analyzed together because the amounts of GalCer are very small, <5%) (Fig. 2.4B), and 
Cer1P (Fig. 2.4C), but the latter was not elevated versus time zero, but rather, against the 
time-matched control because the control cells displayed a curious decrease in Cer1P that 
occurred less in the KLA-treated cells.  DHSM and monohexosyl-DHCer (MH-DHCer) 
also increased for the KLA treated cells versus the control, but the amounts were much 
smaller (Fig. 2.5).  
 The SL that responded most rapidly to KLA was sphinganine (Fig. 2.6A), which 
was significantly different from the control at the earliest time point (0.5 h) and elevated 
by >2-fold between 2 and 8 h, when it began to decline and equaled the control at 24 h.  
Sphingosine also increased, as did Sa1P and S1P, but the sphingoid base 1-phosphates 
increased later (i.e., at 4 h for S1P and 8 h for Sa1P) (Fig. 2.6B). 
 These changes are consistent with de novo SL biosynthesis being higher for KLA-
stimulated RAW264.7 cells because Sa is the first detectable pathway intermediate, 
followed by DHCer then Cer (Fig. 2.1).  Cer might be elevated due to turnover of more 
complex SL (as discussed below), however, the increase in DHCer is not likely to come 
from turnover because this is not equivalent to the decrease in DHSM (c.f. Fig. 2.2A and 




Figure 2.2 KLA Induces Time Dependent Increases in Ceramide and Dihydroceramide 
RAW264.7 cells were incubated with vehicle control (PBS) or KLA (100 ng/mL). Following 
treatment, cells were harvested at the indicated time points for lipid extraction and analysis by LC 
ESI-MS/MS.  A, Amounts of the major chain length subspecies of DHCer.  Data represent the mean 
(n=9). B, Amounts of total DHCer (a summation of all chain lengths) in KLA versus control 
conditions. Data represent the mean + SEM (n = 9); *p < 0.05; **p < 0.001. C, Amounts of the major 
chain length subspecies of Cer. Data represent the mean + SEM (n = 9). D, Amounts of total Cer (a 
summation of all chain lengths) in KLA versus control conditions. Data represent the mean + SEM (n 
= 9); *p < 0.05; **p < 0.001. 
 
 38 
Figure 2.3 Dihydroceramides and Ceramides of RAW264.7 Cells Incubated PBS (Control) or 
KLA for 24 h RAW264.7 cells were incubated with vehicle control (PBS) or KLA (100 ng/mL) for 
24 h then the sphingolipids were analyzed by LC ESI-MS/MS.  The data represent the mean + SEM (n 
= 9); *p < 0.05; **p < 0.001. 
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Figure 2.4 KLA Induces Time Dependent Increases in Ceramide Metabolites RAW264.7 cells 
were incubated with vehicle control (PBS) or KLA (100 ng/mL). Following treatment, cells were 
harvested at the indicated time points for lipid extraction and analysis by LC ESI-MS/MS.  Amounts 
of the major chain length subspecies of Cer metabolites: sphingomyelins (A), monohexosylceramides 
(B), and ceramide 1-phosphates (C) are shown. Data represent the mean (n=9). 
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Figure 2.5 KLA Increases Dihydroceramide Metabolites RAW264.7 cells were incubated for 
various times with vehicle control (PBS) or KLA (100 ng/mL). Following treatment, cells were 
harvested at the indicated time points for lipid extraction and analysis by LC ESI-MS/MS. Data 


























Figure 2.6 KLA Alters the Amount of Sphingoid Bases and Sphingoid Base Phosphates 
RAW264.7 cells were incubated with vehicle control (PBS) or KLA (100 ng/mL). Following 
treatment, cells were harvested at the indicated time points for lipid extraction and analysis by LC 
ESI-MS/MS.  A, Amounts of sphingoid bases, sphinganine and sphingosine. Data represent the mean 
(n=9).   B, Amounts of sphingoid base phosphates, sphinganine 1-phosphate and sphingosine 1-






2.3.2  Correlation of Gene Expression with Metabolite Changes in KLA-treated 
RAW264.7 Cells2 
 As part of the LIPID MAPS studies, the Consortium has also analyzed changes in 
the mRNAs for many of the enzymes of this pathway by microarray analysis 
(www.lipidmaps.org) (Fig. 2.7) and the results for the 24 h time point are displayed in 
Fig. 2.8 using a web-based display tool, GenMAPP v2.1, that was expanded to include 
most of the genes currently known for these steps of de novo SL biosynthesis [147].  
According to this analysis, KLA caused relative increases in mRNAs for both of the 
major subunits of serine palmitoyltransferase (SPT1 and 2), at least one of the Cer 
synthases (CerS4), DHCer desaturase (DES1), and synthases for SM (SMS1) and GlcCer.   
The microarry data also suggest that KLA-stimulated RAW264.7 cells have elevated 
mRNAs for acid sphingomyelinase (SMPD1), sphingosine kinase (SphK1 and 2), and 
S1P lyase (Fig. 2.8), which are consistent with the previous report that LPS induces SM 
turnover [131, 148] and the elevation of sphingoid base phosphates (Fig. 2.6) (although 
elevation of S1P lyase might also indicate that there is elevated cleavage of the latter).  
Mindful of the caveats inherent in microarray analysis, these results suggest that KLA 
affects expression of mRNAs for multiple steps of the pathway, which is consistent with 
the changes in essentially all subcategories of SL (Fig. 2.1-2.6) and the previous literature 




Figure 2.7 mRNA Expression of Genes Involved in Sphingolipid Biosythesis Following KLA 
Stimulation RAW 264.7 cells were harvested 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 8.0, 12.0, 18.0, and 24 h   
after treatment with 100ng/ml KLA. The gene symbols (mus musculus) used at www.lipidmaps.org 
for the enzymes of the sphingolipid pathway:  SPT family (sptlc1 and sptlc2), 3KSR (FVT1), CerS 
(lass2, lass4, lass5, and lass6). DES family (Degs1 and Degs2), SMS 1 (Tmem23), SMS2 
(4933405A16RIK), GalCer Synthase (ugt8a), GlcCer synthase (ugcg), CERK (CERK), CERT 
(Col4a3bp), SMPD1 (SMPD1), SMPD2 (SMPD2), ASAH1 (ASAH1), ASAH2 (ASAH2), ASAH3 




Figure 2.8 KLA Increases mRNA Expression of Genes Involved in Sphingolipid Biosynthesis 
Gene expression data for the sphingolipid metabolic enzymes following 24 h of treatment with KLA 
(100 ng/mL) using the KEGG based microarray analysis tool (GenMAPP v2.1) that has been modified 
in order to display this pathway more completely (www.sphingomap.org). The coloration is log2-fold 
change in expression following treatment with KLA (100 ng/mL) for 24 h from microarray data 
generated by the LIPID MAPS Consortium (www.lipidmaps.org). The sphingolipid metabolites and 
genes (with the gene abbreviations shown in boxes, or enzyme names where gene names are 
ambiguous) are given for the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine (3-
ketoSa) by serine palmitoyltransferase (SPT), which is reduced to sphinganine (Sa), acylated to 
dihydroceramides (DHCer) by (DH)Cer synthases (CerS) and incorporated into more complex DH-
sphingolipids (the 1-phosphate (DHCer1P) sphingomyelins (DHSM), glucosylceramides (DHGlcCer) 
galactosylceramides (DHGalCer) or desaturated to Cer followed by headgroup addition. Also included 
are a number of the catabolic genes, e.g., sphingomyelinases (SMPD), ceramidases (ASAH), 
sphingosine kinases (SphK) for the formation of sphinganine 1-phosphate (Sa1P) and sphingosine 1-
phosphate (S1P), and phosphatases for the reverse reaction and the lyase that cleaves sphingoid base 
1-phosphates to ethanolamine phosphate (EP), hexadecanal (C16:0al) and hexadecenal (C16:1al). 
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2.3.3  Analysis of de novo Sphingolipid Biosynthesis in KLA-Treated RAW264.7  
Cells 
 For further insight into the effect of KLA on SL metabolism, the SPT inhibitor 
ISP1 [150] was used to block de novo SL biosynthesis. As shown in Fig. 2.9A, ISP1 
reduced the KLA-induced elevation of Cer somewhat, completely eliminated the increase 
in MH-Cer, and actually decreased SM (reflecting SM turnover that was not evident in 
the original analysis of SM amount, Fig. 2.4A, because the rate of SM biosynthesis is 
greater than turnover).  Fig. 2.9B shows the effect of ISP1 on KLA treated cells over time 
as well as the individual Cer chain lengths. ISP1 caused an initial decrease in all of the 
Cer subspecies, but only slightly blunted the increase in Cer between 12 and 24 h (c.f., 
Fig. 2.9B and 2.2C).  One of the most interesting features of these Cer data is that they 
display different acyl-chain profiles for the Cer of the cells treated for 24 h with ISP1+ 
KLA versus those treated with KLA alone.  The Cer of KLA-induced RAW264.7 cells is 
relatively similar to that of the controls (i.e., C24:0 > C24:1 > C22:0  (Fig. 2.2C) whereas 
the profile in cells treated with ISP1 + KLA has C24:1 as the predominant very-long-
chain subspecies (Fig. 2.9B).  The latter subspecies distribution is similar to that for SM 
(i.e., C24:1>C24:0) (c.f., Fig. 2.9B with Fig. 2.4A and 2.2C). 
Thus, these results suggest that some of the increases in Cer are due to de novo 
biosynthesis (i.e., ISP1 inhibited). The portion that is not inhibited is likely to come from 
turnover of more complex SL. It is likely that this Cer is derived from SM since the SM 
amounts decrease and the N-acyl chain length distribution of the Cer in the cells treated 
with ISP1 + KLA for 24 h.   A third factor that might affect the Cer subspecies 
distribution of these SL is our observation that KLA alters the fatty acyl-CoA 
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composition of the cells (Fig. 2.10).  Therefore, stable isotope labeling was used to 
monitor the compounds that are made de novo versus via turnover.  
 
Figure 2.9 Effect of ISP1 on Sphingolipid Biosynthesis in KLA-Treated RAW264.7 Cells 
RAW264.7 cells were incubated for 24 h with vehicle control (PBS), KLA (100 ng/mL), ISP1 (1 µM), 
or KLA+ ISP1. For cells treated with KLA + ISP1, ISP1 was added 1 h prior to the addition of KLA.   
Following treatment, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. A, 
Change in the amounts of Cer, MH-Cer, and SM for cells treated with KLA or KLA + ISP1. Data 
represent the mean + SEM (n = 3) B, Amounts of the major chain length subspecies of ceramide in 














Figure 2.10 Amounts of Fatty Acyl-CoAs in RAW264.7 Cells with and without KLA Stimulation 
RAW264.7 cells were incubated for 24 with vehicle control (PBS) or KLA (100 ng/mL). Following 
treatment, cells were harvested at the indicated time points for lipid extraction and analysis by LC 
ESI-MS/MS for the amounts of various chain length fatty acyl-CoAs that are utilized by CerS to make 




2.3.4 Analysis of de novo Sphingolipid Biosynthesis in RAW264.7 Cells by [13C] 
Palmitate Labeling 
 The most direct way to monitor de novo SL biosynthesis is to follow the 
incorporation of [U-13C]palmitate because this precursor is converted into [U-
13C]palmitoyl CoA and utilized in the first step of sphingoid base biosynthesis as well as 
for the N-acylation of sphingoid bases (Fig. 2.1).  Thus, cells will contain four 
isotopically distinct compounds, all of which can be analyzed by LC ESI-MS/MS:  SL 
with only 12C (plus natural abundance 13C, which is corrected for), which reflect pre-
existing SL and those made with endogenous unlabeled palmitate; SL labeled in only the 
sphingoid base backbone (which we term “base-labeled”); SL with a labeled sphingoid 
base plus an amide-linked 13C-fatty acid (which we term “dual-labeled”); and SL labeled 
in only the amide-linked fatty acid, which are likely to be comprised of at least some 12C-
sphingoid bases that have been released by turnover then reacylated using [13C]-fatty 
acyl-CoA.  The base- and dual-labeled SL are unambiguously made by de novo 
biosynthesis, therefore, have been examined in control and KLA-treated cells.  
 The sum of base and dual-labeled [13C]Cer increases over time for both control 
and KLA-treated RAW264.7 cells (Fig. 2.11A), with a plateau between 4 and 12 h then 
decreasing for the control cells, whereas label incorporation continues approximately 
linearly for the entire 24 h for the KLA-treated cells.  Label incorporation has a similar 
subspecies distribution pattern for the control and the KLA-treated cells for the first 12 h 
(Fig. 2.11B) (even though the amounts of labeled Cer is greater in the KLA-treated cells, 
as also displayed in Fig. 2.11A), but the patterns diverge at 24 h, where the C16-Cer 
subspecies predominates in the KLA-treated cells.  As predicted, all of these backbone 
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and dual labeled SL arise from de novo biosynthesis because ISP1 completely eliminated 
the incorporation (Fig. 2.11A and 2.11C, left graph).  In contrast, the right graph of Fig. 
2.11C shows the unlabeled (12C-) Cer in the same cells, which is almost identical to Fig. 
2.9B—i.e., the Cer amounts decrease over the first ~8 h but afterwards increase despite 
the presence of ISP1.  Therefore, this later increase in [12C]Cer must reflect the 
appearance of unlabeled Cer from another source.  
 Overall, these results confirm that de novo biosynthesis accounts for initial 
increases in Cer in KLA-treated RAW264.7 cells and a portion of the increase at 12 and 
24 h, but at 12 and 24 h Cer also arises from an unlabeled pool(s)—i.e. from turnover of 
pre-existing SL (and most likely SM, since turnover of SM has been shown in Fig. 2.9A, 
and the N-acyl-chain distributions of SM and this Cer are similar (c.f., Fig. 2.4A versus 
2.9B and 2.11C, as discussed above). 
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Figure 2.11 Analysis of de novo Sphingolipid Biosynthesis in RAW264.7 Cells by [13C]Palmitate 
Labeling RAW264.7 cells were incubated with 0.1 mM [U-13C]-palmitic acid (as the BSA complex) 
with vehicle control (PBS), KLA (100 ng/mL), ISP1 (1 µM), or KLA+ ISP1. For cells treated with 
KLA + ISP1, ISP1 was added 1 h prior to the addition of KLA for the times shown.  The appearance 
of 13C in newly synthesized sphingolipids was quantified by mass spectrometry as described under 
Materials and Methods. A, Summation of Base (Backbone) labeled and Dual (Backbone and Fatty 
Acid) labeled Cer subspecies. Data represent the mean + SEM (n = 3). B, Summation of Base 
(Backbone) labeled and Dual (Backbone and Fatty Acid) labeled Cer species in cells treated with 
Control (left) or KLA (right) Data represent the mean (n = 3). C, Summation of Base (Backbone) 
labeled and Dual (Backbone and Fatty Acid) labeled Cer species (left) and 12C (unlabeled) Cer species 
(right) in cells treated with KLA + ISP1. Data represent the mean (n = 3). 
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2.3.5  KLA Inhibits Cell Growth and Increases the Size of RAW264.7 Cells 
 In contemplating why the RAW264.7 cells acquire such substantial amounts of 
additional SL (and lipids overall) upon activation, as well as why the [13C]-labeled SL of 
the control cells decrease on a per cell basis between 12 and 24 h (Fig. 2.11A), it 
occurred to us that this might be related to cell growth—i.e., that SL biosynthesized by 
growing cells will be distributed into multiple daughter cells upon division, whereas 
growth inhibited cells that continue to synthesize SL will accumulate them unless 
turnover is more rapid.  Activation of RAW264.7 cells by LPS is known to inhibit cell 
growth [151], and Fig. 2.12A shows that this also occurs with KLA.  Based on the 
measured µg DNA per dish, the KLA-treated cells cease to grow after 4 to 6 h (during 
which the µg DNA increases from 1 to 1.6 µg DNA, or 3.3 to 5.3 x 105 cells, and remains 
at this number at 24 h), whereas, the control cells triple (i.e.; from approximately 1 to 2.9 
µg DNA corresponding to an increase in cell number from 3.3 to 9.6 x 105 cells) in 24 h.  
Therefore, the major contributor to the increase in SL in the KLA-treated cells is that the 
biosynthesized lipids remain with the original cells rather than being divided into 
daughter cells.  The lower graph in Fig. 2.12A shows that ISP1 is also partially growth 
inhibitory. 
 The greater amount of lipid in KLA activated RAW264.7 cells would be 
predicted to increase cell size, and LPS has been reported to increase the diameter of this 
cell line [152].  The diameter of the RAW264.7 cells with and without KLA treatment for 
24 h was estimated by measuring the cell size distribution using bright field microscopy.  
As shown in Fig. 2.12B, the KLA-treated cells appear somewhat larger, and a graph of 
the relative distribution of the measured diameters (Fig. 2.12C) shows that the 
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distribution curve is shifted to the right for KLA-treated cells, and shows a non-Gaussian 
distribution. From these data, the average cell diameters for the control and KLA-
activated cells were calculated to be ~10.5 and ~13.0 microns, respectively.  An increase 
in diameter of this magnitude (24%) would correspond to a ~53% increase in surface area 
(Fig. 2.12D), which is similar to that estimated following LPS treatment of RAW264.7 
cells [153]. 
 Thus, continued SL biosynthesis with an expansion of membrane area (and cell 
size) in RAW264.7 cells that are growth inhibited by KLA is a major contributor to the 
increase in SL content of these cells, and probably the increase in lipid amount overall.  
The difference between the change in cell surface area (1.5 x, although this is only a 
rough approximation) and the change in lipid amount (1.8 x) probably reflects an 
accompanying increase in intracellular membranes.  Activation of the TLR4 receptor of 
RAW264.7 cells by LPS is known to induce the formation of the vacuolar structures 




Figure 2.12 KLA Reduces Cell Number and Increases Cell Size in RAW264.7 Cells   
A, µg DNA per dish following treatment with vehicle control (PBS), KLA (100 ng/mL), ISP1 (1 µM), 
or KLA+ ISP1 for various times. Data represent the mean + SEM (n = 3). B, Representative bright 
field images with measured cellular diameter for control and KLA-treated cells. For each experimental 
condition, 225 cells were analyzed. Data represent the mean. C, Relative cellular diameter and D, 
relative cellular surface area distribution patterns are shown. For each experimental condition, 225 
cells were analyzed. 
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2.3.6 KLA Induces Autophagy in RAW264.7 Cells, and KLA-Induced Autophagy  
is Dependent on de novo Sphingolipid Biosynthesis 
 Autophagosomes are particularly interesting from a SL perspective because 
exogenously added Cer, or cellular accumulation of Cer due to disruption of SL 
metabolism, has been shown to induce autophagy in other cell types [1, 102, 104].  
Studies of autophagy frequently use cells that stably or transiently express a green-
fluorescent-protein (GFP)-tagged LC3 protein (microtubule-associated protein 1 light 
chain 3) [77] that, like wild-type LC3, is recruited from the cytosol to become part of the 
autophagosome due to conjugation of the C-terminal glycine with 
phosphatidylethanolamine [77, 78]; therefore, the appearance and accumulation of GFP-
LC3 puncta is widely used to assess autophagy [77].  
 As shown in Fig. 2.13, KLA treatment of RAW264.7 cells stably expressing GFP-
LC3 induced the characteristic redistribution of GFP-LC3 from diffuse fluorescence 
throughout the cytosol (left panels of Fig. 2.13A) to numerous punctate fluorescent 
vesicles (right panels of Fig. 2.13A). A quantitative analysis of the confocal microscopic 
images revealed that a small but statistically significant increase in the number of cells 
expressing GFP-LC3 puncta and the number of GFP-LC3 puncta/cell following KLA 
treatment can be seen as early as 2 h, but the largest differences are seen later (Fig. 
2.13B).  
 Consistent with these findings, the LIPID MAPS microarray data set for the 
RAW264.7 cells (www.lipidmaps.org) reveal that KLA elevates the mRNAs for 
Atg8/LC3 and Atg12, which are positively correlated with autophagy (Fig. 2.14A) [84, 
85], and an elevation in the lipidated form of LC3 (LC3-II) was detected by Western blot 
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analysis in both RAW264.7 cells stably transfected with GFP-LC3 and untransfected 
RAW264.7 cells (Fig. 2.14B) [65, 77]. Taken together the above data establish that KLA 
induces autophagy in RAW264.7 cells.  
 To determine if de novo SL biosynthesis is required for the induction of 
autophagy by KLA, RAW264.7 cells stably expressing GFP-LC3 were treated with ISP1 
for 1 h then KLA was added and the numbers of autophagosomal puncta were analyzed 
(Fig. 2.15).  By both visual inspection (Fig. 2.15A) and quantitative analysis of the 
confocal images (Fig. 2.15B), it is evident that inhibition of de novo SL biosynthesis by 
ISP1 blocked the appearance of GFP-LC3-associated autophagosomes.  This is doubly 
interesting because it not only links de novo SL biosynthesis with KLA-induced 
autophagy but also establishes that the elevation of Cer due to SL turnover (which was 
minimally affected by ISP1) (Fig. 2.9B and 2.11C) is not sufficient to induce autophagy.  
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Figure 2.13 KLA Induces Autophagy in RAW264.7 Cells RAW264.7 cells stably expressing GFP-
LC3 were incubated for various times with vehicle control (PBS) or KLA (100 ng/mL). A, 
Representative images. B, The number of cells displaying GFP-LC3 puncta (upper panel) and the 
number of GFP-LC3 puncta/cell (lower panel) were quantified using ImageJ. For each experimental 
condition, a minimum of 260 cells/experiment were counted. Data represent mean + SEM (n = 3); # 
(n=2);  *p < 0.05; **p < 0.01. 
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Figure 2.14 Additional Evidence that KLA Induces Autophagy in RAW264.7 Cells   
A, RAW264.7 cells were incubated in the absence (control) or presence of KLA (100 ng/mL), 
harvested at 2, 4, 8, 12, and 24 h and for each time point an Agilent array was used to determine the 
mRNA expression level of various genes including LC3 (Map1LC3B) and Atg12. B, RAW264.7 cells 
were incubated for 24 h with vehicle control (PBS) or KLA (100 ng/mL) prior to immunoblot analysis 









Figure 2.15 KLA-Induced Autophagy is Dependent on de novo Sphingolipid Biosynthesis 
RAW264.7 cells stably expressing GFP-LC3 were incubated for 24 h with vehicle control (PBS), 
KLA (100 ng/mL), ISP1 (1 µM), or KLA+ ISP1. For cells treated with KLA + ISP1, ISP1 was added 
1 h prior to the addition of KLA. A, Representative images.  B, The number of cells displaying GFP-
LC3 puncta (upper panel) and the number of GFP-LC3 puncta/cell were quantified using ImageJ. For 
each experimental condition, a minimum of 195 cells/experiment were counted. Data represent mean 




2.3.7 Confirmation that de novo Sphingolipid Biosynthesis is Required for 
Autophagy using CHO-LYB Cells 
 Since conditions for complete knock-down of de novo SL biosynthesis using 
siRNA have not been established yet for these RAW264.7 cells, the requirement for de 
novo SL biosynthesis for autophagy induction was confirmed using another cell model, 
the CHO-LYB cell line, which lacks SPT activity due to mutation of SPT1 [143].  When 
these cells were transfected with GFP-LC3 and treated with a reagent known to induce 
autophagy, 4-HPR [1, 99, 144], there was no increase in fluorescent puncta versus the 
control (Fig. 2.16).  However, when this cell line has been stably transfected with SPT1 
(CHO-LYB-LCB1 cells) to restore de novo SL biosynthesis [143], it responds to 4-HPR 
with robust accumulation of GFP-LC3 punctate autophagosomes (Fig. 2.16), as has been 
seen in other cell lines [1, 99, 144].  Therefore, these results confirm that de novo SL 
biosynthesis is required for induction of autophagy. 
Figure 2.16 Confirmation that de novo Sphingolipid Biosynthesis is Required for Autophagy 
using CHO-LYB Cells CHO-LYB and CHO-LYB-LCB1 cells transfected with GFP-LC3 were 
incubated with vehicle control (EtOH) or 4-HPR (10 µM) for 24 h. Representative images for each 







2.3.8  Evidence that KLA Promotes the Co-Localization of Ceramide with 
Autophagosomes 
 SL biosynthesis de novo originates in the ER [9] followed by trafficking of Cer 
(and other metabolites) to the GC by vesicular and CERT-mediated processes [154].  
Since the ER and GC are thought to be membrane components for autophagosome 
formation [155-158], it is possible that de novo biosynthesized Cer and/or other SL are 
incorporated into autophagosomes for structural and/or signaling purposes.  To determine 
if Cer is associated with autophagosomes, we examined RAW264.7 cells using an anti-
Cer antibody that has been previously characterized for subcellular localization studies 
[134-139].  In unstimulated RAW264.7 cells, this antibody co-localized mainly in the 
perinuclear, GC, as has been previously observed for other cells using anti-Cer antibodies 
[134] and fluorescent Cer analogs [8] (Fig. 2.17A).  However, following addition of 
KLA, the immunofluorescence clearly shifts to punctate vesicles that co-localize with the 
autophagosomal marker, GFP-LC3 (Fig. 2.17A).  Furthermore, inhibition of de novo SL 
biosynthesis with ISP1 had no noticeable effect on the anti-Cer antibody 
immunofluorescence associated with the GC (in control or KLA-treated cells), but 
blocked the KLA induced co-localization of Cer with autophagosomes (Fig. 2.17A).  The 
quantitative analysis of multiple confocal images shows that this suppression was highly 
significant (Fig. 2.17B) whether expressed as the total number of cells with GFP-LC3 
puncta co-localized with Cer (Fig. 2.17B, upper panel) or as the number of autophagic 
cells (i.e. those cells with 5 or more GFP-LC3 puncta) with GFP-LC3 puncta co-localized 
with Cer (Fig. 11B, lower panel).  The lack of effect of ISP1 on the GC localization is not 
surprising because Cer from SL turnover is known to reach the GC by retrograde 
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trafficking [159, 160].  Thus, these findings are strongly suggestive that the anti-Cer 
antibody immunofluorescence reflects Cer (and possibly related compounds such as 
DHCer) incorporation into autophagosomes in KLA-activated RAW264.7 cells. 
 Cer accumulation has been noted to cause disassembly of the GC [161], therefore, 
to determine if the punctate structures seen in these studies might be due to 
disorganization/fragmentation of the ER/GC network, we also used antibodies against 
GM130, a resident protein found in the cis-Golgi, and BiP/GRP78, a chaperone protein 
found in the ER, to examine the structure of the GC and ER.   As shown in Fig. 11C, 
KLA did not significantly alter the localization of GM130 or BiP/GRP78 suggesting that 
Cer’s assocation with the autophagosome is not due to its ability to disrupt the ER/GC 
(Fig. 2.17C).   
 All together, these findings are strongly suggestive that de novo biosynthesized 
Cer (and possibly related compounds such as DHCer) are incorporation into 
autophagosomes but not via a general recruitment of the ER or GC.  
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Figure 2.17 KLA Promotes the Co-localization of Ceramide with the Autophagosome RAW264.7 
cells stably expressing GFP-LC3 were incubated for 24 h with vehicle control (PBS), KLA (100 
ng/mL), ISP1 (1 µM), or KLA + ISP1. For cells treated with KLA + ISP1, ISP1 was added 1 h prior to 
the addition of KLA.  A, Following treatment, the extra- and intracellular Cer was stained for all 
conditions. Representative images.  B, The number of cells displaying GFP-LC3 puncta co-localized 
with ceramide (upper panel) was quantified using ImageJ. For each experimental condition, a 
minimum of 150 cells/experiment were analyzed for ceramide co-localization. Data represent mean + 
SEM (n = 4). Lower panel, The number of autophagic cells displaying GFP-LC3 puncta co-localized 
with Cer was quantified using ImageJ. For each experimental condition, a minimum total of 40 
autophagic cells were analyzed for Cer co-localization. Data represent mean + SEM (n = 4). *p < 0.05. 
**p < 0.01; ***p < 0.001. C, RAW264.7 cells stably expressing GFP-LC3 were incubated for 24 h 
with vehicle control (PBS) or KLA (100 ng/mL). Following treatment, the GC and ER were stained 
using antibodies against GM130 and BiP, respectively 
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2.4  Discussion 
 These studies have determined the cellular amounts of the SL of RAW264.7 cells 
from the first detectable intermediate (Sa) through Cer and its initial metabolites (SM, 
GlcCer, etc.), and established how KLA, a TLR4 receptor agonist, alters the amounts of 
many of these compounds. Through the use of an inhibitor of de novo SL biosynthesis 
and stable isotope labeling, we found that both control and KLA-stimulated RAW264.7 
cells are actively engaged in de novo SL biosynthesis; however, soon after KLA 
treatment, the cells stop dividing, resulting in an increase in the cell size and SL content.   
 Most of the changes in SL were due to de novo biosynthesis and are reminiscent 
of the induction of SL biosynthesis in liver [129] and a number of extrahepatic tissues 
[130].  Increases in Cer are an interesting exception because it was also derived from 
another source, most likely the turnover of cellular SM, which is also in agreement with 
previously noted activation of sphingomyelinase and production of Cer in LPS treated 
cells [131].  It is intriguing that the amount of Cer that can be attributed to de novo 
biosynthesis when the cells are incubated with [13C]palmitate is similar to the total Cer in 
experiments without stable isotope labeling, and when cells are treated with ISP1 in 
addition to KLA (Fig. 2.2, 2.9, and 2.11).  This suggests that the cells have mechanism(s) 
to maintain some form of “Cer homeostatsis” by coordination of the formation and 
removal of this compound to/from multiple sources. 
We think that one of the most important findings of these studies is that activation of 
RAW264.7 cells not only increased the cellular SL content but also cell size (~24%), 
surface area (~53%), and the production of the intracellular membrane vacuoles termed 
autophagosomes.  Furthermore, de novo SL biosynthesis was shown to be necessary for 
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autophagosome formation, which—to the best of our knowledge—is the first 
demonstration of the requirement for SL for a “normal” biological process for induction 
of autophagy, although exogenous addition of SL, or their endogenous accumulation 
when SL metabolism has been disrupted, has been noted to induce autophagy in other 
cell types [1, 102-105].  Consistent with a requirement for de novo SL biosynthesis for 
autophagy, we found that CHO-LYB cells are refractory to induction of autophagy by 4-
HPR until a functional SPT1 was reintroduced into the cells (Fig. 2.16).  Therefore, SL 
may play an essential role in many, if not all, forms of autophagy. 
 It is not yet known with certainty if the de novo biosynthesized SL(s) required for 
autophagy is (are) (DH)Cer per se, although the anti-Cer antibody co-localization studies 
suggest that this might be the case.  This raises the possibility that the production of 
(DH)Cer and possibly other SL [103] by de novo biosynthesis in the ER might be a 
driving force for formation of the autophagosomal vacuole, in what has been referred to 
as the “membrane extension” step [162] that occurs after many of the associated 
autophagosomal proteins have been recruited.  If this process requires participation by the 
ER, this might explain why elevation of Cer by SL turnover did not appear to be adequate 
for induction of autophagy by KLA in RAW264.7 cells; which is also consistent with the 
previous observation that treatment of HT29 cells with bacterial sphingomyelinase to 
generate Cer had no effect on autophagy induction [102]. Furthermore, since the enzymes 
for de novo Cer biosynthesis reside in the ER [9], it is imaginable that they might be 
recruited into autophagosomes and, perhaps, continue to produce SL there. However, a 
preliminary experiment using antibodies against the first two enzymes in de novo SL 
biosynthesis, serine palmitoyltransferase subunit 1 (SPT1, also called “LCB1”) and 
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3KSR, found no evidence that the enzymatic machinery for de novo SL biosynthesisis is 
recruited to the autophagosome. Therefore, the idea of how ceramide becomes associated 
with the autophagosome is an interesting area for continued study.  
 There are additional reasons to suspect that Cer might play a role in autophagy.  
First, Cer has been identified as a mediator in the ER-localized dissociation of the Beclin-
Bcl-2 complex, which facilitates autophagosomal vesicle nucleation [68, 76, 104].  
Second, activation of macrophages invokes ER stress [163], which is one of the up-
regulators of autophagy [164] and might involve SL as intermediaries or modulators 
[165].  And third, Cer has been shown to inhibit the activation of the Akt/mTOR cascade 
resulting in the induction of autophagy [102], and the microarray analysis by the LIPID 
MAPS Consortium (www.lipidmaps.org) suggests that KLA decreases mTOR mRNA; 
therefore, KLA might induce autophagy through repression of the Akt/mTOR signaling 
pathway at multiple levels.  All of the above might be interrelated, or mean that there are 
multiple roles for SL in autophagy, as has often proven to be the case in other biological 
processes. 
 There is a strong likelihood that additional SL [103] and other lipid categories 
(e.g., phosphatidylethanolamine) [77, 78] are involved in autophagy, and that the 
categories differ among organisms.  In yeast, sterol glycoside appears to be critical for 
membrane extension [162], which suggests that future studies should explore if—by 
“lipid homology”— MH-Cer (GlcCer and/or GalCer) might play a role in induction of 
autophagy in mammalian cells.  Balances among lipid categories might also be important, 
as illustrated by the induction of autophagy by cholesterol overloading [166].  
Considering how many lipid categories are changed by KLA in RAW264.7 cells 
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(www.lipidmaps.org), there are many other possibilities to be explored.  The studies 
described in this chapter have, at least, mapped the changes in SL metabolism in 
activated RAW264.7 cells and demonstrated a direct link between de novo SL 
biosynthesis and autophagy, one of the important cell behaviors of cells of the innate 
immune system.  
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CHAPTER 3 
INHIBITION OF DIHYDROCERAMIDE DESATURASE AND 
PERTURBATION OF CELLULAR SPHINGOLIPID METABOLISM 
BY 4-HYDROXYPALMITANILIDE VERSUS 4-
HYDROXYPHENYLRETINAMIDE (FENRETINIDE): 
IMPLICATIONS FOR MODULATION OF DIHYDROCERAMIDE 
METABOLISM AND CELL FUNCTION BY SYNTHETIC AND 
NATURAL COMPOUNDS 
3.1  Introduction 
 4-HPR is a synthetic retinoid undergoing evaluation as an anti-cancer agent in 
human clinical trials for breast [167, 168], ovarian [169], neuroblastoma [170], lung 
[171] and other [172] cancers.  Its mode of action appears to involve multiple 
mechanisms [173], ultimately resulting in apoptosis [174] and/or autophagic cell death 
[99].  One of its potent cellular effects, which has been proposed to participate in its 
cytotoxicity [175] and induction of autophagy [1], is the alteration of SL metabolism.   
 4-HPR was initially thought to induce SL biosynthesis de novo and elevate Cer 
[175] until analysis of cellular SL using LC ESI-MS/MS revealed that it actually 
increases DHCer and downstream complex DHSL, Sa, and Sa1P [1, 176-178] due to 
blockage of the desaturation of DHCer to Cer [1] in addition to its known increase in de 
novo biosynthesis.  Inhibition of DES has been confirmed by in vitro enzymatic assays 
[178, 179], which also confirmed that the 4-HPR metabolite, 4-oxo-4-HPR, is more 
potent [178, 180], whereas, inhibition is substantially eliminated by methylation of the 
phenolic hydroxyl (i.e., in 4-methoxyphenylretinamide) [179].  The latter observation 
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indicates that the phenolic hydroxyl plays a major role in DES inhibition, but what is not 
yet known is if the retinoid moiety per se is required, or might be substituted by other 
functionalities.  This information could be important because a number of bioactive 
compounds with phenolic substituents, such as resveratrol [109], also elevate DHCer but 
have been assumed to be unlikely to function as direct inhibitors of DES [179]. 
 The current study has explored the factors that account for elevation of DHSL in 
cells treated with 4-HPR and structurally related compounds using Hek293 cells and LC 
ESI-MS/MS for analysis of their effects on cellular SL; and, where pertinent, their effects 
as DES inhibitors have also been examined using in situ and in vitro DES assays.  This 
included the possibility that elevation of de novo biosynthesis per se might cause 
accumulation of DHSL; however, the major finding was that compounds as simple as 4-
hydroxypalmitanilide (4-HPA, palmitic acid in amide linkage with aminophenol) inhibit 
DES, elevate cellular DHSL and induce autophagy, as has been previously noted for 4-
HPR and other molecules which increase DHCer [1, 99, 109, 144, 181]. Moreoever, in 
contrast to 4-HPR, 4-HPA has little effect on cell viability and provides researchers with 
a useful tool for the studying the cellular effects of the accumulation of DHCer – 
particulary cell-fate decisions associated with the induction of autophagy. 
3.2  Experimental Procedures 
3.2.1  Materials 
  The suppliers for the reagents were: Succinimidyl 6-(N(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)hexanoate (NBD-hexanoate succimidyl ester) (Molecular Probes, 
Carlsbad,Ca); C6-NBD-ceramide, C6-NBD-glucosylceramide and C6-NBD-
sphingomyelin (Avanti Polar Lipids, Alabaster, AL); D-erythro-dihydrosphingosine, 
reduced nicotinamide adenine dinucleotide (NADH), N-(4-hydroxyphenyl)retinamide (4-
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HPR)(IUPAC name: (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide), 4-hydroxypalmitanilide (4-HPA), 
4-Acetamidophenol (Sigma Aldrich, St. Louis, MO); Brefeldin A (Epicenter, Madison, 
WI); NADPH-regenerating system (BD Biosciences, Bedford, MA); palmitanilide (PA) 
(TCI America, Portland, OR); D-threo-1-ethylendioxyphenyl-2-palmitoylamino-3-
pyrrolidino-propanol (D-t-oEtDO-P4), a glucosylceramide synthase inhibitor [182] was a 
gift from Dr. James A. Shayman (University of Michigan Medical Center, Ann Arbor, 
MI). 
3.2.2 Cells and Cell Culture 
  Hek293 cells (from the American Type Culture Collection, Mannassas, VA) and 
the SPT1/2 overexpressing cells (previously described) [183] were grown in DMEM/F12 
(MediaTech, Manassas,VA) supplemented with 10% heat-inactivated fetal calf serum 
(Hyclone, Logan, UT) and penicillin (100 U/mL) plus streptomycin (0.1 mg/mL). The 
cells were maintained in a 37°C, 90% relative humidity, and a 5% CO2 environment.   
3.2.3 Synthesis of C6-NBD-Dihydroceramide 
 A solution of 5.9 mg (15 µmol) of succinimidyl 6-(N(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)hexanoate in 0.2 ml of 99.8% DMF was added to a solution of 3.9 mg 
(13µmol) of D-erythro-dihydrosphingosine and 20 µl N,N-di-isopropylethylamine in 0.3 
ml of dry DMF, and the mixture was incubated at 40ºC for 20 h. Following evaporation 
of the solvent, a small portion of the residue was dissolved in CHCl3/CH3OH (1:1, v/v) 
and the purity of the NBD-dihydroceramide was analyzed by TLC on silica gel plates 
using CHCl3/CH3OH/H2O (80:19:1, v/v/v) for the solvent system and detection of the 
C6-NBD-dihydroceramide by fluorescence under UV light.  The purity of the reaction 
product was further confirmed by HPLC analysis (see below). 
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3.2.4 In situ Dihydrocermide Desaturase Assay and Lipid Extraction 
 Hek293 cells (1.4 × 105 cells/well) were seeded into 6-well plates 24 h prior to the 
assay. The synthesized C6-NBD-dihydroceramide (in ethanol) was injected into serum-
free culture medium to achieve a final concentration of up to 5 µM (the final ethanol 
concentration did not exceed 0.5%, v/v), as previously described [184]. The dishes were 
returned to the tissue culture incubator for the indicated time, then the cells were washed 
twice with cold PBS prior to harvesting by scraping into a minimal volume of PBS and 
placed in 13 x 100 mm borosilicate test tubes.  The cells were centrifuged for 2 min in a 
table top centrifuge, the supernatant was removed, and the pellet was re-suspended in 1.4 
ml of CHCl3/CH3OH (1:2, v/v) by brief sonication.  To this was added 1 ml of CHCl3 and 
3 ml of H2O followed by gentle mixing, then the tubes were centrifuged to separate the 
phases.  The lower (CHCl3) layer was collected and the solvent evaporated with an 
AES2000 automatic environmental speedvac (Thermo Savant, Waltham, MA). The 
fluorescent SL were analyzed by HPLC as described below. 
3.2.5 In vitro Dihdyroceramide Desaturase Assay 
 Semi-intact cells were prepared as described by Funakoshi et al. [185], and 
resuspended in Hepes/KCl buffer (H/KCl buffer, 25 mM Hepes-KOH, pH 7.2, 115 mM 
KCl).  Aliquots of the perforated cells were checked with Trypan blue to determine the 
extent of perforation (which was from 90 to 95%) and to determine the protein amount 
using a BCA assay.  The components of the assay mixture were prepared on ice and 
contained 200 µg of protein from the semi-intact cell suspension, 3.33 mM NADH and 
2.6 mM NADPH (as a component of the NADPH-regenerating system) to ensure 
adequate reductants were available for the desaturase activity [15, 186], and 4-HPR at 
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final concentrations of 0 to 10 µM.  H/KCl buffer was added to bring the total volume to 
99 µl, then 1 µl of 500 µM C6-NBD-dihydroceramide (in ethanol) was added, on ice, 
mixed, and the assay tubes were placed in a shaking water bath at 37 ºC for 1 h. The 
reaction was stopped by the addition of 700 µl of CHCl3/CH3OH (1:2, v/v). The lipids of 
interest were extracted by the addition of 230 µl of CHCl3 and 420 µl of 0.1 M KCl. The 
CHCl3 phase was then removed and allowed to evaporate. Following evaporation of 
chloroform, the resulting products were analyzed by HPLC. 
3.2.6 HPLC Analysis of NBD-Sphingolipids 
 HPLC analysis was conducted using a Shimadzu (Kyoto, Japan) Model LC-10AS 
liquid chromatograph with a Waters (Milford, MA) Radial Pak C18 column (4 µm, type 
8NVC184) and 10 µm µBondapak C18 Guard insert, and an isocratic solvent system 
(CH3OH/H2O/H3PO4, 800:200:1.5, v/v/v) at a flow rate of 1 mL/min. The individual 
NBD-SL were detected using a Shimadzu RF-535 spectrofluorometer with an excitation 
wavelength of 460 nm and an emission wavelength of 537 nm, and identified by 
comparison with commercially available C6-NBD-SL (Avanti Polar Lipids, Alabaster, 
AL). 
3.2.7 Lipid Extraction and Analysis by LC ESI-MS/MS 
 The extraction and analysis methods have been thoroughly described [127] and 
the LC ESI-MS/MS was conducted using a Perkin Elmer Series 200 MicroPump system 
coupled to a PE Sciex API 3000 triple quadrupole mass spectrometer (Applied 
Biosystems, Foster City, CA), and a Shimadzu LC-10 AD VP binary pump system 
coupled to a Perkin Elmer Series 200 autoinjector coupled to a 4000 QTrap (Applied 
Biosystems, Foster City, CA) operating in a triple quadrupole mode.   The internal 
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standard cocktail for quantitation was obtained from Avanti Polar Lipids (Alabaster, AL).  
Protein concentration was determined using a BCA Assay Kit (Pierce, Rockford, IL). 
Statistical analysis was performed using a two-tailed Student’s t-test. 
3.2.8 Stable Isotope Labeling of Sphingolipids 
 Stable isotope labeling was conducted using [U-13C]-palmitate as recently 
described [140].  In brief, the [U-13C]-palmitate was prepared as the 1:1 (mol:mol) 
complex with fatty acid-free bovine serum albumin (BSA) as a 1 mM solution in PBS 
which was diluted to 0.1 mM with complete cell culture medium, filter sterilized, and 
added to the cells.  After the indicated times of incubation, the unlabeled (12C-) and the 
three categories of SL labeled with [U-13C]-palmitate (i.e., in the sphingoid base 
backbone alone—which we designate “Base-labeled;” in the fatty acid only—“Fatty acid- 
labeled;” and in both the sphingoid base and fatty acid—“Dual-labeled”) were quantified 
by LC ESI-MS/MS by comparison of the the peak areas of the analytes of interest with 
the spiked internal standards [140].  The sum of the “Base-labeled” and “Dual-labeled” 
data for a given SL subspecies has been used for the unambiguously “de novo” 
biosynthesized molecules since these both have [13C] in the sphingoid base backbone 
from utilization of [U-13C]palmitoyl-CoA by the first enzyme of the pathway, serine 
palmitoyltransferase (Fig. 3.1). 
3.2.9 Viability Studies 
 Viability was monitored using WST-1 (Roche Applied Science, Indianapolis, IN).  
The cells were seeded in 96-well plates at 2 x 104 cells/well for 24 h, then treated with 4-
HPR or 4-HPA for the indicated times. Next, viability was estimated by adding the WST-
1 reagent to the wells and incubating for up to 60 min at 37°C.  The absorbance of the 
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dye was measured at 450 nm.  The data represent n=6 replicates given as mean + SEM 
with evaluation of the statistical significance of differences between groups using a two-
tailed Student’s t-test. 
3.2.10 Western Blotting 
 Hek293 cells were treated with 4-HPA (50 µM) or 4-HPR (5 µM) for 24 h then 
harvested in RIPA buffer (PBS, 1% Nonidet P-40, 0.5% sodium deoxcholate, and 0.1% 
SDS) and solubilized by sonication followed by 30 min of incubation on ice.  After 
centrifugation at 12,000 x g for 10 min at 4°C, and the supernatant was collected and the 
protein amount determined using the BCA Assay Kit (Pierce, Rockford, IL). Aliquots of 
each sample (50 µg of protein) were separated on a 15% SDS-PAGE gel (Bio-Rad, 
Hercules, CA) and transferred to a PVDF membrane (Millipore, Billerica, MA). 
Membranes were blocked in 5% milk/Tris buffered saline containing 0.1% Tween 20 
(TBS-T) for 1 h at room temperature and incubated overnight at 4°C with rabbit anti-
LC3B (1:500) (Cell Signaling Technology, Boston, MA) and mouse anti-ß actin (1:1000) 
(Cell Signaling Technology, Boston, MA) primary antibodies. The blot was washed with 
TBS-T and incubated with horseradish peroxidase conjugated anti-rabbit (Jackson 
ImmunoResearch Laboratories, West Grove, PA) and anti-mouse (Pierce, Rockford IL) 
secondary antibodies for 2 h at room temperature, and analyzed using an enhanced 
chemiluminescent substrate (ECL) (Pierce, Rockford, IL).  
3.3 Results 
3.3.1  4-HPR Increases Dihydroceramide and other Metabolites with the 
Sphinganine Backbone in Hek293 Cells 
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 As has been seen with several cell lines [1, 176-178], 4-HPR does not elevate Cer, 
but rather, causes substantial elevations in DHCer (more than 100-fold versus cells 
treated with only the vehicle) as determined by LC ESI-MS/MS (see middle panels in 
Fig. 3.1; results for specific chain-length subspecies of DHCer and Cer are shown later in 
this chapter (Fig. 3.13)).  This was accompanied by: elevations in downstream DHSL, 
which include DHSM, MH-DHCer (shown on the second rows of Fig. 3.1) and Sa and 
Sa1P (top row, Fig. 3.1); decreases in Cer and MH-Cer but not SM (third row of Fig. 3.1) 
and a decrease in So (bottom row); and a small increase in S1P (lower right panel of Fig. 
3.1).  These results are consistent with the inhibition of DES by 4-HPR as shown by 
layout of these data in a pathway context in Fig. 3.1.   
 The total amount of (DH)SL in the 4-HPR treated cells (the sum of the DHSL + 
SL) was increased by ~2.6 fold when compared with the total (DH)SL of the control (i.e., 
12278 pmol/mg for the 4-HPR-treated cells vs 4736 pmol/mg protein in control), which 
is also indicative that 4-HPR induces de novo SL biosynthesis, as has been noted 
previously [175, 178] (these previous findings are the basis for the “+” arrows at SPT and 
CerS in Fig. 3.1).  This will be experimentally addressed later in this study.  
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Figure 3.1 4-HPR Induces Significant Increases in Total Dihydrosphingolipids in Hek293 Cells 
Hek293 cells were incubated with vehicle control (EtOH) or 4-HPR (5 µM). Following 24 h of 
treatment, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. Data represent the 
mean + SEM (n = 3); *p < 0.05. 
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3.3.2 Direct Evidence for 4-HPR Inhibition of DES and C6-NBD-Dihydroceramide 
Desaturation in Hek293 Cells 
Inhibition of DES by 4-HPR could be demonstrated by both in situ (Fig. 3.2A) 
and in vitro (Fig. 3.2B) assays using C6-NBD-DHCer as the substrate.  The in situ assay 
capitalized on the known ability of NBD-Cer analogs, including NBD-DHCer [184], to 
be taken up by cells and quickly converted to downstream NBD-labeled SL [187, 188].  
Thus, 1 h after C6-NBD-DHCer was added to intact Hek293, analysis of the metabolites 
by HPLC (Fig. 3.2A, left panel) shows that some of the original C6-NBD-DHCer 
remains and at least three metabolites have been produced in essentially equal amounts: 
C6-NBD-dihydroglucosylceramide (DHGlcCer; this was identified as having the Glc 
headgroup by inhibition by D-t-EtDO-P4, as shown in Fig. 3.3)[182], C6-NBD-Cer and 
C6-NBD-GlcCer.  In contrast, when 4-HPR was also added (Fig. 3.2A, right panel), the 
C6-NBD-Cer and C6-NBD-GlcCer are nearly eliminated, as predicted for DES inhibition 
by 4-HPR.  
4-HPR inhibited DES activity when assayed in vitro with semi-permeabilized 
cells (Fig. 3.2B).  We found it difficult to assay DES activity in homogenized Hek293 
cells, which is consistent with the reported lability of this enzyme [15]; however, the 
conversion of C6-NBD-DHCer to C6-NBD-Cer was readily detected when the cells were 
permeabilized using the protocol developed by Hanada and co-workers in studies of Cer 
trafficking by CERT [185], as shown in the left elution profile of Fig. 3.2B (the 
appearance of small amounts of C6-NBD-DHGlcCer might indicate the presence of a 
small fraction of resealed cells).  The production of C6-NBD-Cer was reduced by ~65% 
by 1 µM 4-HPR, and nearly completely blocked by 10 µM (Fig. 3.2B, middle and right 
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elution profiles), which is consistent with the reported [179] IC50 of ~ 2 µM for 4-HPR 
when C8-DHCer was used as the substrate. 
Figure 3.2 4-HPR Inhibits C6-NBD-Dihydroceramide Desaturation in situ and in vitro in Hek293 Cells.  A, 
Hek293 cells were incubated with or without 10 µM 4-HPR for 1 h prior to the addition of 5 µM C6-NBD-DHCer. 
Incubation was continued for an additional hour. The lipids were then extracted and analyzed by reverse phase 
HPLC with detection of the NBD-fluoresence, as described under Materials and Methods.  The fluorescent 
products were identified by comparison with standards.  Abbreviations:  NBD-GlcCer, NBD-glucosylceramide; 
NBD-Cer, NBD-ceramide; NBD-DHGlcCer, NBD-dihydroglucosylceramide; NBD-DHCer, NBD-
dihydroceramide; and NBD-SM, NBD-sphingomyelin.  Data collection was terminated prior to the elution of 
NBD-dihydrosphingomyelin (NBD-DHSM) from the column. B, Semi-intact Hek293 cells were prepared as 
described in the text and incubated with an NADPH regenerating system, 5 µM C6-NBD-DHCer and the shown 
concentrations of 4-HPR. After 60 min at 37°C, the assay was terminated through the addition of lipid extraction 
solvents and analyzed by reverse phase HPLC as described under Materials and Methods. Inhibition was 
quantified by the reduction of peak area of NBD-Cer versus NBD-DHCer. The fluorescent products were 





Fig. 3.3 In situ Assay of DES with C6-NBD-Dihydroceramide in the Presence of an Inhibitor of 
Glucosylceramide Synthase Because C6-NBD-Cer and C6-NBD-DHGlcCer elute very close to each 
other on HPLC, a GlcCer synthase inhibitor (D-threo-1-ethylendioxyphenyl1-2-palmitoylamino-3-
pyrrolidino-propanol, D-t-EtDO-P4) was used to confirm our interpretation of the elution profile.  As 
shown in this figure, pre-treatment of the Hek293 cells with D-t-EtDO-P4 completely eliminated the 
peaks that we had interpreted to be C6-NBD-GlcCer and C6-NBD-DHGlcCer (see Fig. 3.2 in main 
text), which confirmed our assignments for these compounds.  It is also interesting that inhibition of 
glycosylation elevated the amount of free C6-NBD-fatty acid (at the column throughput) and C6-
NBD-DHSM, as one would anticipate due to elimination of one of the branches of (DH)Cer 
metabolism (c.f., pathway shown in Fig. 3.1 of the main text). 
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3.3.3 Does Elevated de novo Sphingolipid Biosynthesis Contribute to 
Accumulation of Dihydrosphingolipids in 4-HPR-Treated Cells? 
Although the accumulation of DHSL in Hek293 cells treated with 4-HPR 
correlated well with inhibition of DES activity in situ and in vitro, there might also be a 
substantial contribution from the elevation of de novo SL biosynthesis by 4-HPR if this 
results in production of DHCer more rapidly than they can be utilized by DES, i.e., 
making the desaturation step rate-limiting.  To test this hypothesis, we compared DHCer 
accumulation in wild-type Hek293 cells and Hek293 cells that overexpress both subunits 
of SPT (referred to as SPT1/2 cells), which have an approximately 6-fold higher SPT 
activity [183].  At both of the time points examined (3 and 6 h), de novo SL biosynthesis 
(as assessed by production of 13C –labeled SL with the label from U-13C-palmitate in the 
backbone sphingoid base) was 5 to 8-fold higher for the SPT1/2 cells (Fig. 3.4A) than the 
Hek293 cells (Fig. 3.4B).  The SPT1/2 cells displayed much higher DHSL than the 
Hek293 cells (c.f. upper graphs in panels A and B); however, the DHCer/Cer ratio (Fig. 
3.4C) was still much lower (~0.25) than that found in Hek293 cells treated with 4-HPR 
(>6) (Fig 3.5A).   
The right panels of Fig. 3.4 display the effects of 4-HPR on the incorporation of 
[13C]palmitate into the sphingoid base backbones of (DH)SL of SPT1/2 cells (Fig. 3.4D) 
and Hek293 cells (Fig. 3.4E).  For the latter, note that the total incorporation of 
[13C]palmitate (~3 nmol/mg protein at 6 h) was close to the sum for the SPT1/2 cells 
without 4-HPR (~5 nmol/mg protein at 6 h), therefore, the SPT1/2 cells appear to be a 
reasonable model to test the hypothesis that elevating the rate of production of DHCer 
from de novo (DH)SL biosynthesis (as occurs in Hek293 cells treated with 4-HPR) might 
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elevate DHSL by making the DES step rate-limiting.  The conclusion from these studies 
is that elevation of the rate of (DH)SL biosynthesis by several fold does, indeed, elevate 
the amounts of DHCer and other DHSL somewhat, but this is likely to account for only a 
small fraction of the elevation of DHSL upon 4-HPR treatment. 
 
 
Figure 3.4 De novo Sphingolipid Biosynthesis from [U-13C]Palmitate by Hek293 Cells and 
SPT1/2 Cells with and without 4-HPR. 
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3.3.4 The Presence of the Retinoid Group is not Essential for Inhibition of DES  
and Dihydrosphingolipid Elevation 
 Previous studies have shown that modification of 4-HPR by introduction of a 
ketone into the cyclopropene ring (4-oxo-4-HPR) of the all trans-retinoic acid (ATRA) 
portion, or by methylation of the phenolic hydroxyl of the aminophenol affect the 
potency of inhibition [179], but not whether these structural components are particularly 
active or essential.  Figure 3.5 shows the effects of the individual components (ATRA in 
panel B and p-aminophenol in panel C) on the DHCer/Cer ratio of Hek293 cells, with the 
not-too-surprising lack of significant effects compared to 4-HPR (Fig. 3.5A) (with 
respect to the retinoid group, 9- and 13-cis-retinoic acids were also negative, data not 
shown).  However, if the ATRA is replaced by a simple acetyl group (4-
acetamidophenol), there was a small but noteworthy elevation in the DHCer/Cer ratio as 
shown both on the same scale as 4-HPR in the lower graph and in an expanded version in 
the upper right region of panel D).   This raised the intriguing possibility that other simple 
alkyl amides—especially ones with longer acyl chains to provide greater 
hydrophobicity—might be able to substitute for the ATRA component of 4-HPR.   
This was examined using an analog with an alkyl chain comparable to that of a 
typical DHCer (C16) in amide linkage with 4-aminophenol (4-hydroxypalmitanilide, 4-
HPA, shown in Fig. 3.6A).  Treatment of Hek293 cells with 1 µM 4-HPA significantly 
increased essentially all N-acyl chain length-DHCer, and the elevation of total DHCer 
with 10 µM 4-HPA begins to approach that of 4-HPR (c.f., Fig. 3.1 and 3.6B). 
Additionally, 10 µM 4-HPA significantly decreased the C16-, C22-, C24:1-, and C24-
subspecies of Cer when compared with control treated cells (Fig. 3.6C).  4-HPA 
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Figure 3.5 Effect of all-trans-Retinoic Acid, 4-Aminophenol, and 4-Acetamidophenol Compared 
to 4-HPR on Dihydroceramide Accumulation in Hek293 Cells Hek293 cells were incubated with 
vehicle control and A, 4-HPR (10 µM), B, ATRA (10 µM), C, 4-aminophenol (200 µM), or  D, 4-
acetamidophenol (100 µM). Following treatment, cells were harvested for lipid extraction and analysis 
by LC ESI-MS/MS. Data represent the mean + (n=3). Ratio of C16DHCer to C16Cer in treatment 
versus control are shown.   
 
significantly increased DHSM and MH-DHCer (Fig. 3.7A and B) as well as Sa and Sa1P 
(Fig. 3.7C) while decreasing SM and MH-Cer (Fig. 3.7A and B) and So (Fig.3.7C), and 
minimally affecting S1P (Fig. 3.7C).   
The optimal alkyl chain length for DES inhibition by this type of analog has not 
been determined, but N-(4-hydroxyphenyl)decanamide was also found to inhibit activity 






















Figure 3.6. Dihydroceramide and Ceramide Species in 4-HPA-Treated Hek293 Cells Hek293 
cells were incubated with vehicle control (EtOH) or 4-HPA (1 µM or 10 µM). Following treatment for 
24 h, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. A, Structure of 4-HPA 
B, Amounts of total DHCer (a summation of all chain lengths) in 4-HPA versus control conditions. 
Data represent the mean + SEM (n = 3); *p < 0.05. C,Amounts of the major chain length subspecies of 
DHCer. Data represent the mean + (n=3); *p < 0.05. D, Amounts of the major chain length subspecies 

























Figure 3.7  (Dihydro)sphingomyelin, Monohexosyl(dihydro)ceramide, Sphingoid 
Bases, and Sphingoid Base Phosphates in 4-HPA-Treated Hek293 Cells Hek293 cells 
were incubated with vehicle control (EtOH) or 4-HPA (10 µM). Following treatment for 24 
h, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. A, Amounts of 
the major chain length subspecies of DHSM and SM. B, Amounts of the major chain length 
subspecies of MH-DHCer and MH-Cer. Data represent the mean + (n=3); *p < 0.05. C, 















Figure 3.8 In vitro Assay of DES with C6-NBD-Dihydroceramide in the Presence of N-(4-
hydroxyphenyl)decanamide Semi-intact Hek293 cells were prepared as described in the text and 
incubated with an NADPH regenerating system, 5 µM C6-NBD-DHCer and the shown concentrations 
of 4-hydroxyphenyldecanamide. After 60 min at 37°C, the assay was terminated through the addition 
of lipid extraction solvents and analyzed by reverse phase HPLC as described under Materials and 
Methods. Inhibition was quantified by the reduction of peak area of NBD-Cer versus NBD-DHCer 
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3.3.5 The Presence of the Phenol Group is Essential for Inhibition of DES and 
Dihydrosphingolipid Elevation 
While treatment of Hek293 cells with 4-HPA largely recapitulates the changes in 
(DH)SL seen with 4-HPR, the same concentrations of palmitanilide (PA), which lacks the 
phenol group, had no effect on total DHCer (Fig. 3.9A) or total Cer (Fig. 3.9B) versus the 
control.  These findings establish that the phenol group of 4-HPA is imperative for the 
effective inhibition of DES, in agreement with the recent report that methylation of the 
phenolic group of 4-HPR reduces its potency [179].  
The fact that the alkyl chain can be as simple as an acetyl (Fig. 3.5), decanoyl 
(Fig. 3.8) or palmitoyl (Figs. 3.6 and 3.7) group suggests that other categories of 
hydrophobic phenols might inhibit DES and elevate DHSL.  Support for this idea has 
been provided by a previously published study that found that resveratrol, a polyphenolic 
bioactive natural product (Fig. 3.10), increased DHCer in a human gastric cancer cell line 
and appeared to inhibit DES activity based on in vitro assay [109] (however, the latter 
activity measurements were made after 16 h of treatment with 50 µM resveratrol, so the 
effect might have been indirect, as was later presumed) [179].  To answer this question, 
we treated Hek293 cells with resveratrol to determine its effect on cellular (DH)SL (Fig. 
3.10A & B) and its inhibition of DES activity in vitro using semi-permeabilized cells 
(Fig. 3.10C).  Resveratrol significantly increased almost every DHCer subspecies shown 
in Fig. 3.10A, and DES inhibition in vitro was evident with sub-µM concentrations, and 
almost completely eliminated by 1 µM (Fig. 3.10C).  Therefore, two distinct categories of 
phenolic compounds that have structures that differ substantially from 4-HPR also inhibit 





Figure 3.9 Comparison of Sphingolipid Composition in 4-HPR-, 4-HPA-, and PA-Treated 
Hek293 Cells Hek293 cells were incubated with vehicle control (EtOH), 4-HPR (1, 5, or 10 µM),  4-
HPA (1, 5, or 10 µM), or PA (1, 5, or 10 µM) . Following treatment for 24 h, cells were harvested for 
lipid extraction and analysis by LC ESI-MS/MS. The structure of PA is shown. A, Amount of total 
DHCer (a summation of all chain lengths). Data represent the mean + SEM (n = 3); *p < 0.05. B, 




Figure 3.10 Resveratrol Increases Dihydroceramide Accumulation and Inhibits 
Dihydroceramide Desaturase in Hek293 Cells A, Hek293 cells were incubated with vehicle control 
(EtOH) or resveratrol (10 µM). Following treatment for 24 h, cells were harvested for lipid extraction 
and analysis by LC ESI-MS/MS. A, Amounts of the major chain length subspecies of DHCer Data 
represent the mean + SEM (n = 3); *p < 0.05. B, Total DHCer (a summation of all chain lengths) Data 
represent the mean + SEM (n = 3); *p < 0.05. C, Semi-intact Hek293 cells were prepared as described 
in the text and incubated with an NADPH regenerating system, 5 µM C6-NBD-DHCer and the shown 
concentrations of resveratrol. After 60 min at 37°C, the assay was terminated through the addition of 
lipid extraction solvents and analyzed by reverse phase HPLC as described under Materials and 
Methods. Formation of NBD-Cer from NBD-DHCer was quantified by HPLC. Data represent average 
± range for duplicate assays. 
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3.3.6 4-HPR and 4-HPA Differentially Affect de novo Sphingolipid Biosynthesis 
There are noteworthy differences between 4-HPA and 4-HPR.  While both elevate 
DHCer to a similar extent at 1 µM, at higher concentrations (5 and 10 µM), the elevation 
of DHCer (and other DHSL) was higher for 4-HPR (Fig. 3.9A) and, conversely, Cer (Fig. 
3.9, lower panel), MH-Cer and SM (Fig. 3.11) are somewhat lower for cells treated with 
5 µM 4-HPR than 4-HPA.  Paradoxically, 10 µM 4-HPR elevates Cer (Fig. 3.9, lower 
panel), SM and MH-Cer (Fig. 3.11); however, these data are collected from fewer cells 
because significant cell death occurs at this concentration (perhaps accounting for the 
higher SEM for some metabolites).  Since both 4-HPA and 4-HPR inhibit DES, one 
possible explanation for the greater increases in (DH)SL by 4-HPR might be its induction 
of de novo SL biosynthesis.   
To consider this possibility, (DH)SL biosynthesis from [U-13C]palmitate was 
compared for cells treated with 4-HPR or 4-HPA and these results (Fig. 3.12) 
recapitulated the differences in DHSL and SL mass noted above—i.e., 4-HPR caused 
greater incorporation of [U-13C]palmitate into the DHSL and greater suppression of de 
novo biosynthesis of [13C]Cer and [13C]MH-Cer, but had higher labeling of [13C]SM that, 
when totaled, reflected a higher level of de novo SL biosynthesis with 4-HPR than with 
4-HPA  (i.e., 478 + 54 pmol/mg protein for 4-HPR-treated cells vs 352 + 28 pmol/mg 
protein for 4-HPA-treated cells). Indeed, when the total incorporation for the control cells 
and the 4-HPA-treated cells are compared (400 + 15 pmol/mg protein and 352 + 28 
pmol/mg protein, respectively), there was no evidence of a change in the rate of de novo 
(DH)SL biosynthesis by 4-HPA, only a redistribution of the subspecies toward higher 
DHSL.  
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This side-by-side comparison also confirmed that there is a large difference in the 
effect of 4-HPR and 4-HPA on cellular Sa (Fig. 3.12C). The increase in Sa in the 4-HPR 
treated cells was ~17-fold greater than the increase with 4-HPA, which would be 
consistent with the induction of de novo SL biosynthesis by 4-HPR. 
Thus, the changes in (DH)SL in cells treated with 10 µM 4-HPR are more 
complicated than for 4-HPA treatment because 4-HPR not only inhibits DES but also 
causes a large increase in the rate of de novo SL biosynthesis, as has been previously 
noted [175, 178].  Another possible contributor to the more complicated SL metabolism 
in cells treated with 4-HPR (which we have not elected to address in these studies) is that 
4-HPR has been reported to increase sphingomyelinase activity in neuroblastoma cell 
lines [189].  The interesting new finding of our studies is that 4-HPA inhibits DES with 








Figure 3.11 Comparison of Sphingomyelin and Monohexosylceramide Composition in 4-HPR-, 
4-HPA-, and PA-Treated Hek293 Cells Hek293 cells were incubated with vehicle control (EtOH), 
4-HPR (1, 5, or 10 µM),  4-HPA (1, 5, or 10 µM), or PA (1, 5, or 10 µM) . Following treatment for 24 
h, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. Amounts of total SM and 
MH-Cer (a summation of all chain lengths). Data represent the mean + SEM (n = 3). 
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Figure 3.12 Analysis of de novo Sphingolipid Biosynthesis in Hek293 Cells by [13C]Palmitate 
Labeling Hek293 cells were incubated with 0.1 mM [U-13C]-palmitic acid (as the BSA complex) 
with vehicle control (EtOH), 4-HPR (10 µM), or 4-HPA (10 µM). Following 6 h of treatment, the 
appearance of 13C in newly synthesized sphingolipids was quantified by mass spectrometry as 
described under Experimental Procedures. A, Summation of Base (Backbone) labeled and Dual 
(Backbone and Fatty Acid) labeled DHCer, MH-DHCer, and DHSM. Data represent the mean + SEM 
(n = 4); *p < 0.05. B, Summation of Base (Backbone) labeled and Dual (Backbone and Fatty Acid) 
labeled Cer, MH-Cer, and SM. Data represent the mean + SEM (n = 4); *p < 0.05. C, Hek293 cells 
were incubated with vehicle control (EtOH), 4-HPR (10 µM), or 4-HPA (10 µM). Following 24 h of 
treatment, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. Amounts of Sa 
are shown. Data represent the mean + SEM (n = 3). D, Viability was assessed using the WST-1 
protocol following 24 and 48 h of treatment. Data represent the mean + SEM (n = 6); *p < 0.05. 
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3.3.7 4-HPA Uncouples Dihydroceramide Elevation and Induction of Autophagy  
from Cytotoxicity 
4-HPR is cytotoxic for many types of cells in culture and this was also seen with 
Hek293 cells treated with 4-HPR but not 4-HPA, as shown in panel D of Fig. 3.12.  
When Hek293 cells were treated with 10 µM 4-HPR, the number of viable cells was 
reduced by about half versus the control after 24 h, and by 48 h there were few viable 
cells (Fig. 3.12D, grey bars).  In contrast, the same concentration of 4-HPA caused no 
reduction in cell viability compared to the control, and appeared to have a slight 
stimulatory effect that was significant by 48 h (Fig.3.12D, black bars). 
This lack of toxicity with 4-HPA was surprising because it has earlier been shown 
that de novo biosynthesis is necessary for 4-HPR toxicity (by experiments using myriocin 
to inhibit SPT) [190-192] therefore, the converse is often assumed—that perturbation of 
SL metabolism induces the toxicity.  To explore this further, experiments were also 
conducted where the concentrations of 4-HPR and 4-HPA were adjusted to elevate 
DHCer to nearly equivalent amounts and determine the (DH)SL profiles and effects on 
cell viability.  For these studies, the cells were incubated with 50 µM 4-HPA or 5 µM 4-
HPR for 24 h, which increased the total amounts of DHCer of the 4-HPA and 4-HPR-
treated cells to ~75% of each other (Fig. 3.13A) and Sa to ca 40% (Fig. 3.13C) versus 
~6% in Fig. 3.12C; however, this caused no noticeable change in the effects of these 
agents on cell viability (Fig. 3.13D). 
All together, these findings make it unlikely that the changes in “bulk” SL 
composition of Hek293 cells per se in response to DES inhibition are responsible for the 
toxicity of 4-HPR, although the combined effect of DES inhibition and induction of de 
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novo SL biosynthesis (with its potential implications for production of bioactive 
compounds in sensitive subcellular compartments) might play a role.  In this context, it is 
noteworthy that the N-acyl-chain length of the DHCer that are elevated by 4-HPR span 
both the long (i.e., C16) and very-long- (C22 and C24) chain subspecies, whereas, the 
profile in 4-HPA treated cells favors the very-long-chain subspecies (C24 and C24:1) 
(Fig. 3.13).  More definitively, the studies have uncoupled DES inhibition and elevations 
in (DH)SL by 4-HPA from cytotoxicity; therefore, this molecule is a useful tool to study 
the affects of perturbing the SL composition of cells (elevation of DHCer, etc.) without 
toxicity. 
The first biological activity that was reported for DHCer was induction of 
autophagy in cells treated with 4-HPR or exogenous short-chain DHCer [1], which is 
interesting in general because SL have not only been shown to induce the formation of 
autophagosomes [1, 102, 104, 105, 193] but also to be required for formation of these 
intracellular vacuoles in response to a physiologically relevant agonist [45].  One of the 
tools that is used to assess autophagy is to analyze the state of the LC3 protein 
(microtubule-associated protein 1 light chain 3), which is present in cells mainly as a 
proteolytically cleaved form (LC3-I) that is conjugated to phosphatidylethanolamine to 
become LC3-II upon induction of autophagy [77-80]. The conversion of LC3-I to LC3-II 
can be followed via SDS-PAGE and Western blotting [77-80, 83]. As shown in Fig. 
3.13D, treatment of Hek293 cells with both 4-HPA (50 µM) and 4-HPR (5 µM) for 24 h 
elevated the lipidated from of LC3 (LC3-II); therefore, although 4-HPA is not cytotoxic 
for these cells, it retains the ability to induce autophagy in Hek293 cells. 
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Figure 3.13 Dose Response Effects of 4-HPR and 4-HPA on Dihydroceramide, Ceramide, 
Sphinganine, Viability, and Autophagy Induction in Hek293 Cells Hek293 cells were incubated 
with vehicle control (EtOH) or 4-HPA (1 µM or 10 µM). Following treatment for 24 h, cells were 
harvested for lipid extraction and analysis by LC ESI-MS/MS. A, Amounts of the total and major 
chain length subspecies of DHCer. Data represent the mean + (n=3); *p < 0.05. B, Amounts of the 
total and major chain length subspecies of Cer. Data represent the mean + SEM (n = 3); *p < 0.05. C, 
Amounts of Sa are shown. Data represent the mean + SEM (n = 3); *p < 0.05. D, Viability was 
assessed using the WST-1 protocol following 24, 48, and 72 h of treatment. Data represent the mean + 




 These studies have determined that in addition to 4-HPR, structurally simpler N-
acyl analogs (4-HPA and 4-hydroxyphenyldecanamide), and resveratrol inhibit DES 
activity and elevate DHCer and other DHSL in Hek293 cells.  Nonetheless, comparison 
of 4-HPR and one of these alternative inhibitors, 4-HPA, reveal interesting differences in 
the SL subspecies that are affected and the cellular responses.   
 This study has not attempted to elucidate the mechanism of DES inhibition 
because the purified enzyme is not available for such studies, but it is noteworthy that a 
phenolic hydroxyl group is a common structural feature, and inhibition has been shown to 
be reduced when the phenolic hydroxyl is methylated for 4-HPR [179] or eliminated for 
PA (this study).  It is likely that all of these compounds are able to access the active site 
of DES, which appears to accommodate compounds with fairly bulky substituents instead 
of the alkyl chains of the natural DHCer substrates as evidenced by its activity with C6-
NBD-DHCer (Fig. 3.14); therefore, the phenol group of all of these compounds—and 
presumably others (Fig. 3.14)—would be predicted to be able to gain access to the active 
site.  Based on analogies with other other lipid desaturases (such as Δ9–stearoyl-CoA 
desaturase) [186, 194, 195], this might interfere with active site elements that participate 
in the redox chemistry (which might also account for inactivation of the enzyme by thiols 
and reactive oxygen species) [15, 196].  
We think that one of the most important findings of these studies is the 
identification of 4-HPA as a novel DES inhibitor that was able to induce autophagy but 
not cytotoxic.  This uncouples the elevation of a substantial number of compounds that 
might have been presumed to mediate the toxicity of 4-HPR (such as some subspecies of 
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DHSL) from cytotoxicity, and provides a tool to study these perturbations of (DH)SL 
content without the complication that the cells are dying.  This also reconciles what had 
appeared to be a paradox:  that inhibiton of DES by 4-HPR is cytotoxic but genetic 
ablation of one or both alleles of the DES enzyme produces homozygous null mice that 
live 8 to 10 weeks following birth and heterozygous mice with no obvious health 
abnormalities [197]. 
Several studies support the role of SL metabolism and particularly increases in 
DHCer in the induction of autophagy [1, 109]. Although, 4-HPA did not induce cell 
death under any of the tested conditions, it did trigger an accumulation of DHCer and 
increase in autophagy equivalent to that of treatment with 4-HPR as concluded from LC 
ESI-MS/MS and LC3-II immunoblot analysis. While autophagy, as a cellular process, is 
most often thought of as a cell survival mechanism in order to aid in the adaptation of 
cellular stress by enabling cells under adverse conditions to degrade cytosolic 
proteins/organelle and generate a supply of essential nutrients, activation of autophagy 
can also be induced as part of a cell death response, and the accumulation of 
autophagosomes is characteristic of “type II” or  “autophagic” cell death [67, 86]. It is 
interesting that 4-HPR and 4-HPA seem to represent the dual nature of autophagy in cell 
survival, as shown following treatment with 4-HPA, and cell death, as shown following 
treatment with 4-HPR, suggesting that SL may play a role in many, if not all forms, of 
autophagy.  
In conclusion, the studies described have mapped the concentration dependent 
changes in DHSL and SL metabolism in 4-HPR treated Hek293 cells as a result of both 
alterations in de novo biosynthesis and inhibition of DES, identified key structural 
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features which mediate DES inhibition, and distinguished 4-HPA as a novel non-toxic 
DES inhibitor, which may be a useful tool for future studies involving the cell-type 
specific effects of DES inhibition and the accumulation of DHCer and its metabolites,  
specifically studies of the dual role of DHCer in determining cell-fate decision following 






Figure 3.14 Structural Diversity of Compounds used to Monitor DES Inhibition 
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CHAPTER 4 
PALMITATE ENHANCES FENRETINIDE INDUCED CELL DEATH 
IN MCF7 BREAST CANCER CELLS 
4.1  Introduction 
 4-HPR, a synthetic derivative of retinoic acid, has been -- and continues to be -- 
evaluated in preclinical models and clinical trials for use in both the prevention and 
therapy of various cancers, with a special emphasis on breast cancer as a result of its 
ability to selectively accumulate in breast tissues [99, 172, 198]. A recent phase III 
clinical trial, with a 15-year follow-up study, indicates that 4-HPR treatment significantly 
reduces the incidence of second breast cancer recurrence in women diagnosed with Stage 
I breast cancer [99, 172]. This long-term analysis provides evidence for the persistent 
chemopreventive effects of 4-HPR even after therapeutic intervention is completed and 
makes it an attractive agent for continued evaluation in breast cancer therapy [172].   
4-HPR appears to function by multiple mechanisms in tumor cell lines with the 
end result of caspase-dependent apoptotic [100, 172, 174, 199-201] and/or caspase-
independent autophagic cell death [1, 99]. Interestingly, it has been demonstrated that 
many malignant cancers acquire genetic deletions or mutations [69, 96] that render them 
resistant to classical apoptotic cell death induced by many anti-cancer therapies including 
4-HPR [99]. For example, a MCF7 breast cancer cell that does not express caspase-3, is 
resistant to caspase-dependent apoptotic cell death [97-99]. Therefore, the ability of 4-
HPR to induce multiple forms of cell death suggests that this agent may be of therapeutic 
efficacy in cancer cells with deregulated apoptotic pathways [99]. One such component 
of 4-HPR-induced cytotoxicity, which might contribute to the regulation of caspase-
independent autophagic cell death, is the alteration of SL metabolic pathways, as 
bioactive SL species, including Cer, S1P, and most recently DHCer, have been shown to 
mediate autophagic pathways [1, 102-104]. Furthermore, 4-HPR has been previously 
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reported to increase DHCer and its metabolites as much as 10-fold, as analyzed LC ESI-
MS/MS [Chapter 3 and [1, 176-178]]. The accumulation of these DHSL is the result of 
both an increase in de novo biosynthesis [Chapter 3 and [175, 178]], as well as the 
inhibition of DES [Chapter 3 and [179]]. Thus, this study, described in Chapter 4, has 
confirmed the ability of 4-HPR to induce autophagic cell death in MCF7 cells, quantified 
the changes in the SL and DHSL species, and established the requirement of de novo SL 
biosynthesis in the induction of autophagy, suggesting that the production of SL 
mediators are essential for 4-HPR-induced autophagic cell death.   
In addition, an emerging strategy in breast cancer therapy is to design multidrug 
combinations to enhance single-agent-induced cell death and increase the efficacy of 
chemotherapeutic intervention [172, 176, 198], and SL might be useful in this regard 
because a strong association has been found between de novo SL biosynthesis and 4-
HPR-mediated cell death. Thus, we hypothesized that an agent, that would increase de 
novo biosynthesis, would enhance cell killing and improve chemotherapeutic efficacy. To 
this end, we investigated the effect of 4-HPR on MCF7 cells in the presence of palmitate 
(Pal), a precursor and known inducer of de novo SL biosynthesis [145, 202], as well as in 
the presence of oleate (OA), which appears to reduce SL biosynthesis [145, 202]. The 
addition of Pal was found to be effective at enhancing cell killing, while OA protected 
cells from 4-HPR-induced cytotoxicty. Surprisingly, analysis of the SL by LC-ESI 
MS/MS revealed that combined treatment with 4-HPR and Pal or OA had little effect on 
the total DHCer when compared with 4-HPR treatment alone; however, these 
combinations did affect the distribution of the subspecies of DHCer. This suggests that 
the interplay between various subspecies of DHCer may be an important mediator of the 
opposing roles of Pal and OA on 4-HPR-induced cytotoxicity. It was further shown that 
while the protective effects of OA on 4-HPR-induced cytotoxcity could be due to 
augmentation of autophagic cell death, the effects of Pal are more complex. None-the-
less, these studies suggest that although the ability of Pal to enhance 4-HPR-induced cell 
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death is due to a surprisingly unsuspected level of complexity, the efficacy of 4-HPR may 
be improved by the addition of Pal to current treatment regimens.   
4.2  Experimental Procedures 
4.2.1    Materials 
  The suppliers for the reagents were: Fenretinide (4-HPR), Palmitate (Pal), and 
Oleate (OA), (Sigma Aldrich, St. Louis, MO); C2-Ceramide, C2-Dihydroceramide, and 
the internal standard cocktail for SL analysis by LC ESI-MS/MS (Ceramide/Sphingoid 
Internal Standard Mixture II, LM-6005) (Avanti Polar Lipids, Alabaster, AL); fatty acid-
free BSA (Calbiochem, La Jolla, CA); myriocin/ISP1 (Biomol, Plymouth Meeting, PA); 
rabbit polyclonal LC3B antibody, rabbit monoclonal p62 antibogy, and mouse ß actin 
monoclonal antibody (Cell Signaling Technology, Boston, MA)  
4.2.2    Cells and Cell Culture 
MCF7 breast cancer cells were obtained from the American Type Culture 
Collection (ATCC) (Manassas, VA) and grown in MEM (MediaTech, Manassas VA) 
supplemented with 10% heat-inactivated fetal calf serum (HyClone Logan, UT), 
penicillin (100 U/mL) plus streptomycin (0.1mg/mL), nonessential amino acids, and 
sodium pyruvate (1mM). The cells were maintained in a 37°C, 90% relative humidity, 
5% CO2 environment. All cell culture conditions, unless otherwise noted, followed the 
standard protocol recommended by the ATCC.   
4.2.3 Lipid Extraction and Analysis by LC-ESI MS/MS 
The extraction and analysis method has been thoroughly described [127, 140]. 
The mass spectrometry data were collected using a PE Sciex API 3000 triple quadrupole 
and a 4000 quadrupole linear-ion trap mass spectrometer. For quantification, the samples 
were spiked with the internal standard cocktail (Avanti Polar Lipids, Alabaster, AL).  
Protein concentration was quantified using the BCA Assay Kit (Pierce, Rockford, IL). 
Statistical analysis was performed using a two-tailed Student’s t-test. 
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4.2.4 Confocal Immunofluorescence Microscopy 
MCF7 cells stably expressing GFP-LC3 were cultured on glass coverslips (VWR, 
Inc. West Chester, PA) in 24-well plates. Following treatment, cells were fixed with 4% 
formaldehyde for 15 minutes.  Fixed cells were rinsed in PBS, and the nucleic acids were 
stained by incubating fixed cells with 1 µg/mL Hoechst 3342 for 7 min at room 
temperature.  Stained cells were rinsed in PBS and mounted in Fluoromount G (Southern 
Biotechnology Associates, Inc., Birmingham, AL) prior to observation under a Zeiss 
LSM 510 inverted laser scanning confocal microscope (Heidelberg, Germany).  Images 
were collected with the resident Zeiss confocal microscope software and analyzed using 
ImageJ version 1.41a (National Institute of Health). The ImageJ plug-in Analyze 
Particles was used to identify “autophagosomes” as defined by a threshold value of 159-
255 [141] and a particle size of 0.07 to 7 µm2 [142]. Statistical analysis was performed 
using a two-tailed Student’s t-test. 
4.2.5 Generation of MCF7 Cells Stably Expressing GFP-LC3 
LC3A cDNA was obtained from Origene. To generate N-terminal GFP-tagged 
LC3, the LC3A gene was amplified using the following gene-specific primers: 5'-
ATGCCCTCAGACCGGCCTTT-3' and 5'-GAAGCCGAAGGTTTCCTGGGAGG-3'. 
The PCR fragment corresponding to the coding sequence of LC3A was then cloned into 
pEGFP-C2/SmaI (Clonetech, Mountain View, CA) resulting pEGFP-C2-LC3A. 
Sequencing was used to confirm the fidelity of the construct.  
MCF7 cells stably expressing GFP-LC3 were generated by transfection with 
pEFGP-C2-LC3A.  Transfection was performed in 100-mm dishes (3.0 x 106 cells/dish) 
with 6 µg plasmid DNA/plate with GeneJuice® (Novagen; EMD Biosciences, San 
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Diego, CA) according to the manufacturer’s protocol.  Following overnight exposure, 
cells were washed with PBS and selected in media containing 600 µg/mL of G418 
(Sigma-Aldrich; St. Louis, Mo) for 14 days.  The media was changed every other day. 
After two weeks, pools of G418 resistant clones were sorted by FACS analysis, and the 
fluorescent cell population was cloned by limiting dilution in order to establish 
fluorescent colonies originating from a single cell. To confirm the presence of the GFP-
LC3 protein, GFP-LC3 cells were analyzed by Western blotting using an anti-GFP 
antibody (Invitrogen; Carlsbad, Ca). In order to confirm localization of the LC3, GFP-
LC3-transfected MCF7 cells were cultured on 12 mm cover slips (VWR; West Chester, 
PA). Following exposure to C2-ceramide (Avanti Polar Lipids; Alabaster, AL), a known 
inducer of autophagy in MCF7 cells [102] for 24 hrs, cells were fixed in 4% 
formaldehyde and analyzed by fluorescence confocal microscopy.  
4.2.6 Viability Analysis 
 Viability was monitored by measuring the metabolic conversion of a water-
soluble tetrazolium salt, WST-1 (Roche Applied Science, Indianapolis, IN), into 
formazan by mitochondrial dehydrogenases. The amount of formazan produced is 
proportional to the number of live cells and is expressed as cellular viability. For this 
procedure, cells were seeded in 96-well plates at 1 x 104 cells/well for 24 hours. Cells 
were then treated with the indicated reagents for 24, 48, or 72 h, and assays were 
performed by adding WST-1 directly to the culture wells and incubating them for 120 
minutes at 37°C. Plates were then read by a scanning multiwell spectrophotometer by 
measuring the absorbance of the dye with a wavelength of 450 nm and 650 nm. The 
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reported values are equal to (absorbance450nm- absorbance650 nm).  Statistical analysis was 
performed using a two-tailed Student’s t-test. 
4.2.7 Western Blotting 
 MCF7 cells were treated with the indicated reagent for 24 h and harvested in 
RIPA buffer (PBS, 1% Nonidet P-40, 0.5% sodium deoxcholate, and 0.1% SDS). Cells 
were then lysed by sonication followed by 30 min incubation on ice. Lysates were 
centrifuged at 12,000 x g for 10 min at 4°C, and the protein concentration of the 
supernatant was determined using the BCA Assay Kit (Pierce, Rockford, IL). Aliquots of 
each sample (30 µg of protein) were separated on a 12% SDS-PAGE gel (Bio-Rad, 
Hercules, CA) and transferred to a PVDF membrane (Millipore, Billerica, MA). 
Membranes were blocked in 5% milk/Tris buffered saline containing 0.1% Tween 20 
(TBS-T) for 1 hr at room temperature and incubated overnight at 4°C with rabbit anti-
LC3B (1:300) (Cell Signaling Technology, Boston, MA), rabbit anti-p62 (1:400) (Cell 
Signaling Technology, Boston, MA), or mouse anti-ß actin (1:1000) (Cell Signaling 
Technology, Boston, MA) primary antibodies. The blot was washed with TBS-T and 
incubated with horseradish peroxidase conjugated anti-rabbit (Jackson ImmunoResearch 
Laboratories, West Grove, PA) or anti-mouse (Pierce, Rockford IL) secondary antibodies 
for 2 hrs at room temperature. Protein expression was determined using an enhanced 
chemiluminescent substrate (ECL) (Pierce, Rockford, IL). 
4.3 Results 
4.3.1 4-HPR Induces Autophagic Cell Death in MCF7 Breast Cancer Cells 
 MCF7 cells are well known to be caspase-3 deficient, which prevents them from 
undergoing classical apoptotic cell death and renders them resistant to many 
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pharmacological agents [97-99] that proceed through such mechanisms, such as 4-HPR. 
However MCF7 cells are sensitive to 4-HPR, in agreement with a previous study [99], 
with a significant loss in cell viability beginning 48 h after treatment when compared 
with control treated cells (Fig. 4.1A). This decrease in cell viability has been attributed to 
the induction of autophagic cell death as an alternative to caspase-dependent cell death 
[99].  
In order to support this finding, autophagy was analyzed using MCF7 cells stably 
expressing a green-fluorescent-protein (GFP)-tagged LC3 protein (microtubule-
associated protein 1 light chain 3), which like wild-type LC3, is recruited from the 
cytosol to become part of the autophagosome due to conjugation of the C-terminal 
glycine with phosphatidylethanolamine [77, 78]; therefore, the appearance and 
accumulation of GFP-LC3 puncta can be used to assess autophagy [77, 79, 80]. As 
shown in Fig. 4.1B, 4-HPR treatment of MCF7 cells stably expressing GFP-LC3 induced 
the characteristic redistribution of GFP-LC3 from diffuse fluorescence throughout the 
cytosol to numerous punctate fluorescent vesicles. A quantitative analysis of the confocal 
microscopic images revealed a statistically significant increase in both the number of 
cells expressing GFP-LC3 puncta, as well as the number of GFP-LC3 puncta/cell 
following 4-HPR treatment (Fig. 4.1C). For this analysis, C2-DHCer and C2-Cer were 
included as positive controls, as they are known inducers of autophagy [1, 102]. These 
results are in agreement with a previously published finding and confirm that 4-HPR is 
effective at inducing autophagic cell death in the apoptotic defective, MCF7 breast cancer 






Figure 4.1 4-HPR Induces Autophagic Cell Death in MCF7 Cells A, MCF7 cells were incubated 
with vehicle control (EtOH) or 4-HPR (10 µM). Viability was assessed using the WST-1 protocol 
following 24, 48, and 72 h of treatment. Data represent the mean + SEM (n = 18); *p < 0.05. B. MCF7 
cells stably expressing GFP-LC3 were incubated with vehicle control (EtOH), 4-HPR (10 µM), C2-
DHCer (25 µM), or C2Cer (25 µM). Representative images are shown. C, The numbers of cells 
displaying GFP-LC3 puncta, as well as the number of GFP-LC3 puncta/cell were quantified using 
ImageJ. For each experimental condition, a minimum of 548 cells were counted. Data represent mean 
+ SEM (n = 4); # (n=3);  *p < 0.05. 
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4.3.2    4-HPR Increases Dihydrosphingolipids in MCF7 Breast Cancer Cells 
 The induction of autophagic cell death is interesting from a SL perspective, as the 
exogenous addition, as well as the cellular accumulation of various SL species, including 
DHCer (Fig. 4.1B), has been shown to induce the formation of vacuolar autophagosomes 
and participate in autophagic cell death in various cell types including MCF7 cells [1, 
102, 106, 110]. 4-HPR has been previously reported to elicit increases in DHSL in 
several human cancer cell lines, including prostate (DU145), ovarian (MCF7/AdrR and 
A2780), and neuroblastoma (SMS-KCRN) [1, 176-178], as well as non-transformed 
Hek293 cells [Chapter 3]. In Figure 4.2, these findings are extended to the MCF7 breast 
cancer cell line. Treatment of MCF7 cells with 4-HPR significantly increases all 
measured subspecies of DHCer and total DHCer when compared with control treated 
cells after 24 h (Fig. 4.2A). Additionally, 4-HPR significantly increases the subspecies of 
the metabolites of DHCer, DHSM and MH-DHCer (Fig. 4.2B-C).  The accumulation of 
these DHSL has been found to be the result of both an increase in de novo biosynthesis, 
as 4-HPR has been shown to stimulate SPT and CerS activity [175, 178], and the 
inhibition of DES [Chapter 3 and [179]].   
As would be expected following DES inhibition, treatment of MCF7 cells with 4-
HPR decreases many of the subspecies of Cer including, C22, C24:1, C24, and C26 (Fig. 
4.3A). Curiously, the C16-subspecies of Cer significantly increases (Fig. 4.3A).  This 
increase could be the result of the turnover of the C16-subspecies of SM, as LC-ESI 
MS/MS analysis finds a significant decrease in this subspecies (and others) (Fig. 4.3B), 
and 4-HPR has previously reported to activate sphingomyelinase [189]. Likewise, the 
significant increase in the C24-subspecies of SM could be the result of the metabolism of 
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residual long-chain Cer species. These observations suggest that cells are attempting to 
maintain Cer and SM homeostasis by coordinating the formation and removal of these 
molecules, as has been described following the activation of RAW264.7 macrophage 
cells [Chapter 2 and [45]]. Further support for this idea is provided by the analysis of the 
total amounts of cellular Cer and SM, which change very little despite significant changes 
in specific chain lengths (Fig. 4.3A-B).  Additionally, 4-HPR also alters the cellular 
amounts of another metabolite of Cer, MH-Cer (Fig. 4.3C). Significant decreases in the 
C22-, C24:1-, C24-, and C26:1-subspecies, as well as total MH-Cer, were found 
following treatment of MCF7 for 4-HPR for 24 h. In addition to these changes in DHCer 
and Cer and their metabolites, 4-HPR treatment of MCF7 cells was also marked by 
significant increases in Sa and Sa1P but not So and S1P (Fig. 4.4), as has been reported 
for other cell types [176]. Taken together, the above data establishes that 4-HPR 
treatment of MCF7 cells induces an accumulation of DHSL, while decreasing or 
changing Cer containing SL very little, and suggests that 4-HPR-induced autophagic cell 
death of MCF7 cells could be the result of alterations in SL metabolism.  
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Figure 4.2 4-HPR Increases Dihydroceramide and its Metabolites in MCF7 Cells MCF7 cells 
were incubated with vehicle control (EtOH) or 4-HPR (10 µM). Following 24 h of treatment, cells 
were harvested for lipid extraction and analysis by LC ESI-MS/MS. A, Amounts of the major chain 
length subspecies of DHCer and total DHCer (a summation of all chain lengths). B, Amounts of the 
major chain length subspecies of DHSM and total DHSM (a summation of all chain lengths). C, 
Amounts of the major chain length subspecies of MH-DHCer and total MH-DHCer (a summation of 
all chain lengths). For all reported species, data represent the mean + SEM (n=3); *p < 0.05. 
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Figure 4.3 Ceramide and its Metabolites in 4-HPR-Treated MCF7 Cells MCF7 cells were 
incubated with vehicle control (EtOH) or 4-HPR (10 µM). Following 24 h of treatment, cells were 
harvested for lipid extraction and analysis by LC ESI-MS/MS. A, Amounts of the major chain length 
subspecies of Cer and total Cer (a summation of all chain lengths). B, Amounts of the major chain 
length subspecies of SM and total SM (a summation of all chain lengths). C, Amounts of the major 
chain length subspecies of MH-Cer and total MH-Cer (a summation of all chain lengths). For all 
















Figure 4.4 Sphingoid Bases and Sphingoid Base Phosphates in 4-HPR-Treated MCF7 Cells  
MCF7 cells were incubated with vehicle control (EtOH) or 4-HPR (10 µM). Following treatment for 
24 h, cells were harvested for lipid extraction and analysis by LC ESI-MS/MS. Amounts of sphingoid 
bases, Sa and So, as well as amounts of sphingoid base phosphates, Sa1P and S1P. Data represent the 
mean + SEM (n = 3); *p < 0.05. 
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4.3.3    4-HPR-Induced Autophagy Requires de novo Sphingolipid Biosynthesis  
In order to determine if de novo SL biosynthesis is required for the induction of 
autophagy, and presumably autophagic cell death, following treatment with 4-HPR 
MCF7 cells stably expressing GFP-LC3 were treated with ISP1, an inhibitor of SPT 
which blocks de novo SL biosynthesis [150], for 1 h followed by the addition of 4-HPR 
and analysis of autophagosomal puncta.  As shown in Figure 4.5, both the visual 
inspection (Fig. 4.5A) and quantitative analysis (Fig. 4.5B) of the confocal images 
reveals that the inhibition of de novo biosynthesis by ISP1 blocks the appearance of GFP-
LC3-associated autophagosomes suggesting that SL biosynthesis is an important 
determinant of autophagic cell death following treatment of MCF7 cells with 4-HPR. 
Furthermore, this idea is consistent with the requirement of de novo SL biosynthesis in 4-









Figure 4.5 4-HPR-Induced Autophagy is Dependent on de novo Sphingolipid Biosynthesis. 
MCF7 cells stably expressing GFP-LC3 were incubated for 24 h with vehicle control (EtOH), 4-HPR 
(10 µM), ISP1 (1 µM), or 4-HPR + ISP1. For cells treated with 4-HPR + ISP1, ISP1 was added 1 h 
prior to the addition of 4-HPR. A, Representative images.  B, The numbers of cells displaying GFP-
LC3 puncta, as well as the number of GFP-LC3 puncta/cell were quantified using ImageJ. For each 
experimental condition, a minimum of 425 cells were counted. Data represent mean + SEM (n = 4); # 
(n=3);  *p < 0.05. 
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4.3.4  Palmitate, but not Oleate, Enhances 4-HPR-Induced Cell Death.  
Treatment of cells with Pal, has been shown to increase the rate of de novo SL 
biosynthesis; whereas treatment with OA was inhibitory [145, 202]. Since de novo SL 
biosynthesis is required for 4-HPR induced autophagy, it is possible that concurrent 
treatment with Pal and 4-HPR could enhance cell killing by further increasing the 
production of bioactive SL mediators; while treatment with OA may protect cells from 4-
HPR-induced cell death by decreasing these metabolites. The data in Fig. 4.6 reveals that 
4-HPR’s cytotoxicity was significantly enhanced by the inclusion of Pal when compared 
with both control treated and 4-HPR alone treated cells. Interestingly, a significant loss in 
viability was apparent after 24 h of concurrent treatment with 4-HPR and Pal; whereas 4-
HPR alone did not result in significant cell death until at least 48 h post-treatment. 
Cellular viability was not significantly affected by the addition of Pal alone (Fig. 4.6), 
which is consistent with a previously reported finding that Pal induces lipotoxicity in 
ERBB2-positive (BT474 and MDA-MB-361) but not ERBB2-negative (MCF7) breast 
cancer cells [203]. Furthermore, the addition of OA alone was not toxic, and in contrast 
to Pal, the addition of OA significantly decreased the cytotoxicity of 4-HPR.  
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Figure 4.6 Palmitate, but not, Oleate Enhances 4-HPR-Induced Cell Death MCF7 cells were 
incubated with vehicle control (EtOH), 4-HPR (10 µM), Pal (0.1 mM), Pal + 4-HPR, OA (0.1mM), or 
OA + 4-HPR. Viability was assessed using the WST-1 protocol following 24, 48, or 72 h of treatment. 
Data represent the mean + SEM (n = 30). 
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4.3.5  Effects of Palmitate and Oleate on 4-HPR-Induced Alterations of 
Sphingolipid Metabolism 
The cytotoxic effects of 4-HPR are thought to be due to increases in DHCer [1]. 
The ability of Pal to upregulate de novo biosynthesis [145, 202] suggests that the 
enhanced cytotoxicity of concurrent treatment with Pal and 4-HPR when compared with 
4-HPR alone may be the result of further increases in DHCer. Surprisingly, as shown in 
Fig. 4.7A, the 4-HPR-induced accumulation of total DHCer was not significantly affected 
by the addition of Pal or OA when compared with 4-HPR treatment alone. However, 
these treatment combinations, Pal and 4-HPR, as well as OA and 4-HPR did drastically 
affect the chain length distribution of DHCer subspecies when compared with 4-HPR 
alone. As shown in Fig 4.7A, the addition of Pal significantly increases the 4-HPR-
induced accumulation of the C16-, C18-, C20-, and C22-subspecies of DHCer; while 
significantly decreasing the C24:1 subspecies. In contrast, the addition of OA 
significantly decreases the 4-HPR-induced accumulation of the C16-, C18-, C20-, and 
C22-subspecies of DHCer; while significantly increasing the C24:1 subspecies (Fig. 
4.7A). Interestingly, this sort of subspecies-specific regulation seems to be a common 
theme when deciding cell fate, as treatment of Hek293 cells with a non-toxic DES 
inhibitor, 4-HPA, also resulted in a preferential increase in C24:1 subspecies of DHCer; 
whereas the cytotoxic 4-HPR favored an accumulation of the C16- and C18-subspecies 
[Chapter 3]. In addition, Pal nor OA alone significantly altered total DHCer or total Cer 




Figure 4.7 Effects of Palmitate and Oleate on 4-HPR-Induced Alterations of Sphingolipid 
Metabolism MCF7 cells were incubated with vehicle control (EtOH), 4-HPR (10 µM), Pal + 4-HPR, 
or OA + 4-HPR. Following treatment for 24 h, cells were harvested for lipid extraction and analysis 
by LC ESI-MS/MS. A, Amounts of the major chain length subspecies of Cer and total Cer (a 
summation of all chain lengths). B, Amounts of the major chain length subspecies of DHCer and total 
DHCer (a summation of all chain lengths). For all reported species, data represent the mean + SEM 
(n=3); *p < 0.05. 
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4.3.6 Effect of Palmitate and Oleate on 4-HPR-Induced Autophagy and 
Autophagic Degradation 
 To further characterize the mechanism of the opposing effects of Pal and OA on 
4-HPR-induced cell death in MCF7 cells, alterations in autophagy were monitored by 
following the conversion of LC3-I to LC3-II using SDS-PAGE and Western blotting [79, 
80, 83]. Although molecular weight of LC3-II is greater than that of LC3-I, LC3-II 
experiences an increased mobility and migrates faster than LC3-I in SDS-PAGE due to 
the extreme hydrophobicity of LC3-II following its conjugation with 
phosphatidylethanolamine, which is necessary for autophagosome formation [79, 80, 83]. 
Therefore, the amount of LC3-II correlates with autophagosome formation, and thus, it 
can be used as an indicator of autophagy induction [79, 80, 83]. As shown in Fig. 4.8, the 
addition of Pal or OA alone did not enhance the conversion of LC3-I to LC3-II in MCF7 
cells, but instead slightly decreased the level of LC3-II when compared with control 
treated cells. These results suggest that Pal and OA treatment alone are not effective at 
inducing autophagy in MCF7 cells. Furthermore, this decrease in basal autophagy levels 
may account for the slight increase in viability seen following treatment of MCF7 cells 
with Pal or OA alone for 24 h (Fig. 4.8).  Although concurrent treatment of MCF7 breast 
cancer cells with Pal and 4-HPR did significantly enhance cellular toxicity when 
compared with 4-HPR alone (Fig. 4.6), the improved efficacy of this combination does 
not seem to be the result of increased autophagy induction, as the 4-HPR-induced 
increase in the conversion of LC3-I to LC3-II was not enhanced by the addition of Pal. In 
contrast, concurrent treatment with OA and 4-HPR decreases LC3-II levels when 
compared with 4-HPR-treatment alone (Fig. 4.8), suggesting a decrease in autophagy 
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induction and consistent with the ability of OA to protect cells from 4-HPR-induced 
cytotoxicity.  
 Moreover, these results were confirmed by monitoring the cellular level of p62. 
Because p62 is a selective substrate for the autophagic pathway, monitoring endogenous 
p62 levels is often used as a marker for enhanced [as noted by decreases in p62] or 
suppressed [as noted by increases in p62] autophagic degradation or in this case, 
autophagic cell death [204, 205]. As shown in Fig 4.8, treatment with Pal and OA alone 
slightly increased the accumulation of p62 when compared with control treated cells 
suggesting an abrogation of basal level autophagy induction and autophagic cell death 
consistent with the slight increase in cell viability noted above.  Also consistent, the 
combined treatment of MCF7 cells with Pal and 4-HPR did not enhance 4-HPR-induced 
p62 degradation; whereas, the addition of OA to 4-HPR treatment prevented p62 
degradation. Taken together, these results suggest that while the protective effects of OA 
on 4-HPR-induced cell death may be due to a decrease in the induction autophagy and 
autophagic cell death, the addition of Pal does not enhance toxicity through modulation 
of the autophagic pathway. 
Figure 4.8 Effect of Palmitate and Oleate on 4-HPR-Induced Autophagy and Autophagic 
Degradation MCF7 cells were incubated with vehicle control (EtOH), 4-HPR (10 µM), Pal (0.1 mM), 
Pal + 4-HPR, OA (0.1mM), or OA + 4-HPR. Following treatment for 24 h, cells were harvested for 
western blot analysis of LC3 and p62. Two bands were obtained for LC3, the cytosolic LC3-I and the 
autophagosomal LC3-II. ß-actin was used as a loading control. 
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4.4 Discussion 
 4-HPR has been encouraging as a breast cancer chemopreventive and therapeutic 
agent in clinical trials [99, 172]. Furthermore, the promise of 4-HPR as a therapeutic 
agent is enhanced by its unique ability to activate the autophagic cell death pathway when 
the apoptotic pathway is deregulated, a characteristic not shared by other 
chemotherapeutic agents such as cisplatin and etoposide [99]. Interestingly, this idea 
proves to be particularly important when considering therapy for breast cancer, as a 
recent study of malignant breast tissue samples revealed that 75% of the analyzed tissues 
were apoptotic defective [101]. With this in mind, this study first confirmed the ability of 
4-HPR to activate the autophagic pathway in the caspase-3-defective MCF7 breast cancer 
cell line (Fig. 4.1B-C). One mechanism whereby 4-HPR has been reported to induce 
autophagy in other cancer cell lines is via increases in DHCer [1], and LC ESI-MS/MS 
analyses has revealed that treatment of MCF7 cells with 4-HPR results in significant 
increases in DHCer and other DHSL within this cell line (Fig. 4.2), which is likely due to 
the concurrent stimulation of de novo biosynthesis [Chapter 3 and [175]] and inhibition 
of DES [Chapter 3 and [179]]. Furthermore, de novo SL biosynthesis was shown to be 
necessary for autophagosome formation (Fig. 4.5), as has also been recently reported for 
the induction of autophagy in other cellular systems [Chapter 2 and [45]]. 
 Because combination chemotherapy is emerging as a viable strategy to improve 
single-agent efficacy and SL biosynthesis was found in this and other studies to be 
important in 4-HPR-mediated cell death [172, 176, 190, 198], this study sought to 
determine if the administration of 4-HPR in combination with a precursor of de novo SL 
biosynthesis, Pal, would increase toxicity in breast cancer cells. The results demonstrated 
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that Pal enhanced 4-HPR-induced cytotoxicity in breast cancer cells, while the addition 
of OA protected MCF7 cells from 4-HPR-induced cyotoxiciy (Fig. 4.6). Interestingly, the 
addition of serine, a second precursor of de novo SL biosynthesis, had no effect on 4-
HPR-induced cytotoxicity (data not shown). This lack of response might be linked the 
metabolism of extracellular serine to alpha-ketoglutarate [206], which contributes to 
glutaminolysis, an important pathway responsible for energy production and proliferation 
in breast cancer cells [207, 208].  
 To explore the biological basis for the opposing effects of Pal and OA on 4-HPR-
induced cytotoxicity, the effects of these fatty acids on SL metabolism were investigated. 
Surprisingly, combination treatment with Pal and 4-HPR, as well as OA and 4-HPR, 
minimally affected total DHCer and DHCer subspecies when compared to 4-HPR alone 
(Fig. 4.7). Moreover, treatment of cells with either Pal or OA alone also decreased total 
(DH)Cer, as well as most (DH)Cer subspecies when compared with control treated cells 
(data not shown). These results were unexpected for Pal, as it is a known inducer of SL 
biosynthesis [145, 202]. Three hypotheses can be considered to explain these 
observations: (1) Pal decreases de novo SL biosynthesis in MCF7 cells; (2) Pal increases 
the turnover of (DH)Cer to more complex (DH)SL in MCF7 cells; and (3) Pal enhances 
the extracellular export of SL. The first hypothesis is unlikely because Pal is a well-
documented inducer of de novo biosynthesis in numerous cell lines [145, 202, 209]; the 
second hypothesis is also not likely because all measured categories of SL decreased 
following the addition of Pal (data not shown). Interestingly, there is strong rationale for 
the third hypothesis because it is well established that tumor cells, secrete small 
membrane vesicles termed exosomes, both in vivo and in vitro [210-214]. Furthermore, a 
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previous study has found exosomes to be enriched in Cer and other SL including SM 
[215], while a more recent study has reported that Pal is able to trigger the release of 
exosomes [216, 217]. Therefore, it is possible that while the cellular decreases in 
(DH)Cer following treatment with OA could be due to its ability to inhibit SL 
biosynthesis, the changes seen following Pal treatment may be the result of the Pal-
induced release of (DH)Cer-containing exosomes into the extracelluar environment.
 Although total DHCer levels were not significantly affected, the addition of Pal 
and OA to 4-HPR did alter the chain length distribution of the subspecies of DHCer when 
compared with 4-HPR alone (Fig. 4.7). This effect could be due to a shift in the fatty 
acyl-CoA distribution and thereby substrate availability for the CerS family of enzymes. 
The consequences of this regulation are intriguing, as they suggest that preferential 
increases in C16 and C18 DHCer, following treatment with Pal and 4-HPR, as well as the 
preferential increase in C24:1 DHCer, following the addition of OA to 4-HPR treatment, 
may be important in determining the opposing effects of these fatty acids on 4-HPR-
induced cell death.  
 In continuing to explore the basis for the opposing effects of Pal and OA on 4-
HPR-induced cytotoxicity, the ability of these fatty acids to differentially regulate 
autophagy induction and autophagic degradation was analyzed. The protective effects of 
OA on 4-HPR-induced cytoxicity can be explained by its ability to decrease both the 
induction of autophagy, as shown by a decrease in the conversion of LC3-I to LC3-II, as 
well autophagic degradation, as shown by an accumulation of a specific substrate for 
autophagic degradation (p62), when compared with 4-HPR-treatment alone. In contrast, 
the regulation of enhanced cell death following the addition of Pal to 4-HPR treatment is 
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much more complex. Interestingly, combination treatment with Pal and 4-HPR did not 
enhance 4-HPR-induced autophagy or autophagic degradation suggesting that this 
combination may activate a second cell death pathway, which is responsible for the 
increased cell killing. Furthermore, this concept of combining agents, which activate cell 
death via multiple mechanisms, is an active area of study for breast cancer researchers as 
a way to improve therapeutic efficacy and minimize therapeutic resistance [172].  
 In conclusion, this study has demonstrated that Pal induces particular alterations 
in SL metabolism and enhances 4-HPR-induced cell death in MCF7 cells. These changes 
are likely to be the result of multiple mechanisms, and warrant further study because the 
combination of Pal and 4-HPR could be clinically useful.  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 SL are a complex family of molecules [2] that participate in many facets of cell 
structure and function [35, 60]. Therefore, the use of “-omic” approaches – i.e., to 
analyze as many as possible of the molecular species, mRNAs for pathway genes, etc. – 
is likely to uncover interesting, and sometimes unexpected, links between their 
metabolism, cell behavior, and disease [1, 31, 218]. Using the multi-faceted approach of 
lipidomic and genomic analyses combined with cell biology techniques, these studies 
integrate various aspects of SL biology in order to obtain a more clearly defined ‘big 
picture’ of the cellular effects of different agents, KLA and 4-HPR, on SL metabolism 
and the associated functional consequences (Fig. 5.1A-B). In addition, these studies have 
bridged two major paradigms of the biological consequences of altered SL metabolism 
(i.e, the role of SL in lipotoxicity and the role of SL in cancer therapy) in order to develop 
a new strategy for the enhancement of current cancer therapies (Fig. 5.1C).  
Activation of the macrophage cell with LPS has been reported to elevate Cer by 
either the induction of turnover of pre-existing SL [115, 131, 219-221] in some studies or 
by stimulation of de novo biosynthesis [222] in others. Through the use of KLA, a 
homogenous preparation of the component of LPS specific for TLR4 receptor activation 
[128], as well as LC ESI-MS/MS [127] and microarray analysis (www.lipidmaps.org), 
the study described in Chapter 2 and [45] has reconciled these seemingly contradictory 
findings in order to provide a more complete picture of what is going within the 
macrophage cell with regard to SL biosynthesis and metabolism following activation. 
Incubation of RAW264.7 cells, a macrophage-like cell line, with KLA induces significant 
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increases in cellular SL [Chapter 2; Figs. 2.1-2.6 and [45]]. The additional SL arise 
primarily from de novo SL biosynthesis based on labeling with [U-13C]palmitate and 
inhibition by ISP1; however, increases in Cer are also due to elevated turnover [Chapter 
2; Figs. 2.9 and 2.11 and [45]]. Consistent with these metabolite changes, microarray 
analysis provided additional support for this idea of dual regulation of Cer production 
revealing that KLA elevated the mRNAs for not only enzymes of the biosynthetic 
pathway such as SPT, CerS, and DES but also enzymes of the turnover pathway such as 
acid sphingomyelinase (SMPD1) [Chapter 2; Figs 2.7-2.8 and [45]].  Therefore, the use 
of this multi-faceted lipidomic approach has changed how we must view SL metabolism 
in activated macrophage cells from inducing de novo SL biosynthesis OR activating of 
the turnover pathway to inducing de novo SL biosynthesis AND activating the turnover 
pathway (Fig. 5.1A). Furthermore, it is not surprising that the cells would have 
mechanism(s) to coordinate the formation and removal of this bioactive species in order 
to maintain some level of homeostasis.  
In LPS-activated macrophages, the functional implications of increases in Cer 
resulting from the turnover pathway have been extensively explored as depicted in Fig. 
5.1A; whereas the consequences of the upregulation of de novo biosynthesis is less 
understood.  Cer resulting from the turnover of pre-existing SL species, namely SM, has 
been found to be essential for the assembly and activation of the TLR4 complex [219], 
responsible for increases in protein kinase C zeta  (PKCζ) [220], extracellular signal-
regulated kinase 1 and 2 (ERK1/2) [220], and cyclooxygenase 2 (COX-2) [221] enzyme 
activities, and necessary for the activation of inducible nitric oxide synthase (iNOS) and 
the production of nitric oxide [115]. Interestingly, nothing was known about the 
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biological purpose of Cer generated from de novo biosynthesis with the exception that it 
is involved in the release of arachidonic acid [222], a substrate for the generation of 
prostaglandins and leukotrienes. Therefore, increasing knowledge of signaling pathways 
regulated by de novo biosynthesis became an essential goal of these studies in order to 
continue to build a more complete picture of macrophage activation. Chapter 2 and [45] 
established that autophagosome formation is induced following KLA activation of 
macrophage cells (Fig. 2.13-2.14), which might be related to the increase in Cer, and 
perhaps other SL, because exogenous addition, or endogenous accumulation, of Cer is 
sufficient to induce autophagy [102, 104, 105]. Indeed, inhibition of de novo SL 
biosythesis prevented the accumulation of autophagic vacuoles in KLA-treated 
RAW264.7 cells [Chapter 2; Fig. 2.15 and [45]].  Furthermore, immunohistochemical 
analysis of the KLA-treated cells found Cer co-localized with autophagosomes, which 
was inhibited by ISP1 [Chapter 2; Fig. 2.17 and [45]]. These findings are strongly 
suggestive that elevation of Cer by KLA treatment of RAW264.7 cells is essential for 
induction of autophagy, and that the Cer must be derived from de novo biosynthesis 
because autophagosomes were not seen in ISP1-treated cells.  
In addition to uncovering a novel role for de novo biosynthesized SL in 
macrophage activation, this study also found that KLA, as has been reported for LPS 
[151], inhibits cell growth [Chapter 2; Fig. 2.12 and [45]].  Although the role of Cer and 
other SL in KLA-induced growth inhibition is unclear, it is easy to envision that 
regulation of this cellular process represents the importance of the dual mechanism of Cer 
production from both turnover and de novo biosynthesis. As discussed above, Cer 
resulting from the turnover of SM has been found to increase the activity of ERK1/2 
 127 
[220], highly conserved serine/threonine kinase isoforms whose activation has been 
found to inhibit cell-cycle progression leading to growth arrest [223, 224]. One can 
hypothesize that activation of macrophage cells with LPS or KLA could induce 
sphingomyelinase at the cell surface in order to promote the formation of Cer and 
activation of ERK1/2. In turn ERK1/2 translocates from the cytoplasm to the nucleus 
where it mediates cell cycle arrest in the G2/M phase, as has been reported for 
macrophages exposed to cadmium [225]. This inhibition of proliferation concurrent with 
continued SL biosynthesis due to upregulation of the de novo pathway results in an 
expansion of membrane area (and cell size) as the newly biosynthesized lipids remain 
with the original cells rather than being divided into daughter cells [as discussed in 
Chapter 2 and [45]].  In turn, Cer (and other metabolites) resulting from increased de 
novo biosynthesis in ER then provide the driving force for formation of the 
autophagosomal membrane [as discussed in Chapter 2 and [45]]. Because the ER is 
thought to be a key organelle in autophagic membrane biogenesis [155, 156] Cer’s 
localization within the autophagosome suggests that it may be important in the formation 
of the limiting membrane by participating in ER-targeted signaling events. Furthermore, 
this may explain why elevation of Cer by SL turnover alone did not appear to be adequate 
for induction of autophagy following growth arrest by KLA in RAW264.7 cells [Chapter 
2 and [45]]. Additionally, the idea is intriguing because several recent studies have found 
that autophagosome formation is associated with cell cycle arrest in the G2/M phase 
[226-229]. Thus, the interconnectivity of Cer production from both turnover and de novo 
biosynthesis could help to regulate multiple cellular processes in order to promote the 
innate immune response and clearance of pathogens in macrophage cells. 
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This study [Chapter 2 and [45]] provided the most comprehensive 
‘sphingolipidomic’ analysis of activated macrophages to date and demonstrated a direct 
link between KLA induced de novo SL biosynthesis and autophagy, which not only 
deepens our understanding of macrophage biology but also reveals a new facet of SL 
biology and innate immunity. This opens the door to future studies to define the 
contribution of specific Cer subspecies in the induction of autophagy. It will be 
additionally interesting to determine the interrelationship between KLA-induced 
autophagy and inhibition of proliferation. These may be linked through mTOR because 
Cer has been shown to inhibit the activation of the mTOR cascade resulting in the 
induction of autophagy [102], and microarray data generated by the LIPID MAPS 
Consortium (www.lipidmaps.org) revealed a decrease in the mRNA levels of mTOR in 
KLA treated RAW264.7 cells. Thus, there are correlates with both the induction of 
autophagy and changes in SL metabolism, suggesting a possible mechanism of KLA 
induced autophagy through Cer mediated repression of the mTOR signaling pathway. 
More recently, addition of exogenous Cer1P has been found to stimulate macrophage 
proliferation via activation of mTOR [230]. As noted in Chapter 2 and [45], Cer1P was 
one of the few SL species not elevated versus time zero control following treatment with 
KLA. Therefore, it would be interesting to determine if Cer1P and Cer serve as a ‘one-
two punch’ to repress cytosolic mTOR activation and ER-localized mTOR activation 
following KLA stimulation resulting in growth arrest and autophagy.  
The studies described herein have not only expanded our knowledge of alterations 
in SL metabolism and the associated consequences following macrophage activation but 
have also improved our understanding of the mechanisms of action of the 
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chemotherapeutic agent, 4-HPR (Fig. 5.1B). In Chapter 2 and [45], the chemotherapeutic 
agent and known inducer of autophagy, 4-HPR, was a useful tool in confirming the 
requirement of de novo SL biosythesis in the induction of autophagy. Furthermore, 4-
HPR has been reported to increase DHCer and other DHSL by increasing de novo 
biosynthesis as a result of the coordinate activation of SPT and CerS [175], by activating 
the turnover of pre-existing SL through activation of sphingomyelinase [189], and by 
inhibiting the DES enzyme [179].  In Chapter 3, a ‘sphingolipidomic’ analysis reconciled 
these seemingly contradictory obsevations by providing a more accurate assessment of 
the alterations in SL metabolism, using Hek293 cells as a model system. As has been 
reported for other cell lines, 4-HPR significantly increases the DHSL content of Hek293 
cells (Chapter 3; Fig 3.1), and this effect is primarily due to the inhibition of DES 
(Chapter 3; Figs. 3.2 and 3.3).  
Because of the prominent role of DES inhibition in the elevation of DHSL, this 
study additionally examined which structural features of 4-HPR (Fig. 5.1B) contribute to 
its inhibition of DES by comparing 4-HPR, its individual constituents (ATRA and 4-
aminophenol), and analogs where ATRA was replaced by a simple fatty amide (including 
4-HPA).  These comparisons, which included analysis of the DHSL by mass 
spectrometry with complementary in situ and in vitro DES assays where appropriate, 
revealed that the retinoid moiety is not essential for DES inhibition (Chapter 3; Fig. 3.5) 
and (Fig. 5.1B), and the elevation of DHSL could be recapitulated with 4-HPA (Chapter 
3; Fig. 3.6). Furthermore, many other phenols, including resveratrol, were also inhibitors 
(Chapter 3; Fig. 3.10).  When 4-HPR and 4-HPA were added at concentrations that 
elevated DHSL to comparable levels, both were equivalent in induction of autophagy 
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(Chapter 3; Fig. 3.13), but 4-HPA was not cytotoxic, in stark contrast to 4-HPR (Chapter 
3; Fig. 3.13).  
It is noteworthy that in addition to their opposing effects on toxicity, these DES 
inhibitors also differently affect the N-acyl-chain-length distribution of the DHCer 
subspecies (Chapter 3; Fig. 3.13), with 4-HPR increasing both the long (i.e., C16) and 
very-long- (C22 and C24) chain subspecies, whereas, 4-HPA increases mainly the very-
long-chain subspecies (C24:1). This differential regulation provides an interesting avenue 
for future study to determine if the opposing effects of 4-HPR and 4-HPA on cellular 
toxicity are the result of altered regulation of CerS family members, that define which 
fatty acyl-CoAs are used to form distinct DHCer subspecies [1, 3, 11-13]. Studies by 
others have, indeed, found that increases in CerS1 activity [231-233], which regulate the 
synthesis of C18-SL, and CerS5 and CerS6 activity [231, 233, 234], which regulate the 
synthesis of C16-SL, are responsible for the cellular toxicity of chemotherapeutic agents 
and combination therapies. In contrast, increases in CerS2 activity [233, 234], which 
produces C24- and C24:1-SL, was found to offer protection from ionizing radiation 
therapy. Thus, these studies provide further evidence that activation of specific CerSs 
generate pro-death (CerS1, CerS5, and CerS6) versus pro-survival (CerS2) signals, and 
suggests that the ability of 4-HPR to preferentially promote larger increases in C16- and 
C18-DHCer might play a role in its cytotoxicity; whereas 4-HPA preferentially increases 
C24- and C24:1-DHCer, and thus, is not toxic. Using siRNA technology and other 
recently developed inhibitors [235], it will be interesting to continue to investigate this 
phenomena, particularly in the regulation of autophagy and autophagic cell death, which 
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suggests the possibility of species-specific functions for DHCer, that until this point has 
only been considered for the subspecies of Cer [233].  
In addition to the potential role of subspecies-specific functions in contributing to 
the opposing effects of 4-HPR and 4-HPA on cell viability, a second mechanism could 
also be considered. A recent study by Zhang, et al. reported the ability of arsenic trioxide 
to alter SL metabolism through increases in both de novo biosynthesis, as well as the 
hydrolysis of SM [236]. This dual regulation was associated with the downreglation of 
matrix metalloproteinase-9 (MMP-9), an endoproteinase known to be important in 
metastasis, which prevented carcinoma cell invasion resulting in subsequent cell death 
[236]. It would be interesting to compare the effects of 4-HPR and 4-HPA on MMP-9 
expression in order to determine if the ability of 4-HPR to activate de novo biosynthesis, 
in addition to inhibiting DES and in contrast to 4-HPA (Chapter 3; Fig. 12), is critical in 
its ability to mediate a cell-death response.  
Additionally, while this study has not attempted to elucidate the mechanism of 
DES inhibition, it is interesting to speculate about the importance of phenolic group. The 
phenol group is hypothesized to interfere with electron transport. DES, like the Δ9–
stearoyl-CoA desaturase [194] and the Δ1–alkyl desaturase [195], is part of a multi-
enzyme complex, which consists of coupled reactions that transport electrons from 
NAD(P)H to the terminal desaturase leading to the reduction of oxygen [186]. Oxidation 
of phenols can form phenoxyl radicals that are either further oxidized to yield quinones or 
reduced back to the phenol by cellular reductants [237]. Interestingly, cell lines 
responsive to 4HPR treatment were found to have a lower cellular antioxidant thiol levels 
[238]. Therefore, DES inhibition by 4-HPR and other phenolic compounds may be 
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dependent on the dual mechanism of the quinoid derivative (which increase when cellular 
reductants decrease) to behave directly as an electron acceptor shunting electrons away 
from the desaturase electron transport chain and indirectly through the generation of 
reactive oxygen species (ROS) leading to changes in cellular redox status, which has 
been recently shown to potently inhibit desaturase activity [196]. Furthermore, it can be 
envisioned that the presence of the fatty acyl-chain in 4-HPR and 4-HPA has enough 
structural similarity with DHCer for these molecules to fit into the binding pocket of the 
enzyme, perhaps positioning the phenol near the redox center. This would also explain 
why 4-aminophenol and 4-acetamidophenol caused little or no DES inhibition (Chapter 
3; Fig. 3.5).  
The requirement appears to be for a hydrophobic group rather than an alkyl chain 
since resveratrol was also found to be an effective inhibitor of DES activity in vitro 
(Chapter 3; Fig. 3.10). Indeed, the multiple phenolic groups of resveratrol may 
compensate for the presence of the acyl chain by adding enough bulkiness for the 
molecule to fit into the DES binding pocket. Furthermore, once in the pocket, the 
multiple phenol groups of resveratrol may increase inhibition efficiency through the 
formation of multiple quinoid derivatives resulting in the increased ability of resveratrol 
to shunt electrons away from the DES electron transport chain. Additional support for 
this idea is provided by our identification of numerous other polyphenolic compounds 
which inhibit DES activity with an IC50 of < 25 µM including genistein, with three 
phenolic hydroxyl groups, curcumin, with two phenolic hydroxyl groups, and quercetin, 
with four phenolic hydroxyl groups (unpublished observations). 
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The studies described herein have not only expanded our previous view of the 
effects of macrophage activation and chemotherapeutic intervention on SL metabolism 
and the associated functional consequences, but have also bridged two major themes of 
SL research: the role of SL in lipotoxicity and the role of SL in cancer therapy (Fig. 
5.1C).  
Epidemiological studies have found a positive correlation between diets high in 
saturated fats and the development of insulin resistance and complications associated 
with metabolic disease [209, 239]. The dependence of de novo SL biosynthesis on one of 
the most abundant dietary saturated fatty acids [240], Pal, made this pathway an attractive 
target for the investigation of the mechanisms associated with lipotoxicity [239], a 
collective term often used to describe the adverse effects associated with fatty acid 
accumulation including cell death and dysfunction [241]. Indeed, numerous studies, as 
reviewed by Dr. Scott Summers, have linked the production of the bioactive SL 
metabolite Cer to saturated fatty acid-induced lipotoxic processes [239]. While Cer is 
likely only one of several nutrient metabolites responsible for this phenomenon, 
inhibition of the de novo SL biosynthetic pathway negated the effects of fatty acid 
induced-toxicity suggesting that Pal and aberrant de novo SL biosynthesis are key players 
in lipotoxic processes [239].  Additionally, alterations in SL metabolism, particularly 
decreases in Cer production, have been found to be important in the protective role of 
diets high in unsaturated fatty acids, such as OA [209, 239].  
In contrast to the desire to decrease or limit the production of bioactive SL 
mediators, like Cer, in order to combat/prevent lipotoxicity, many cancer therapies seek 
to increase the cellular levels of SL mediators, including Cer and DHCer, as a mechanism 
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to induce cell death, and these molecules have been implicated in mediating the effects of 
many chemopreventive agents [112, 242, 243]. For example, increases in endogenous 
Cer have been found to contribute to the cell death response induced by radiation therapy, 
etoposide, doxorubicin, and daunorubicin, inter alia [112, 242, 243]. Furthermore, the 
accumulation of DHCer following treatment with 4-HPR was found to induce cell cycle 
arrest in neuroblastoma cells [177, 243], as well as stimulate autophagic cell death in 
MCF7 breast cancer cells [Chapter 4; Fig. 4.1 and [99]]. With this in mind, an attractive 
strategy to increase the efficacy of cancer therapy became to combine the concept of Pal-
induced aberrant SL biosynthesis with chemotherapeutic agents, such as 4-HPR, whose 
mechanisms of action has been found to depend on the production of bioactive SL 
mediators (Fig. 5.1C). To this end, the study described in Chapter 4 of this work 
examined if the single agent efficacy of 4-HPR could be enhanced by the addition Pal. 
Indeed, it was found that the addition of Pal was effective at increasing 4-HPR induced 
cell death in MCF7 breast cancer cells (Chapter 4; Fig. 4.6) suggesting that the 
combination of Pal and 4-HPR may be clinically useful in enhancing the efficacy of 4-
HPR.   
In addition to its ability to enhance the single agent efficacy of 4-HPR, a second 
interesting reason why this combination warrants continued evaluation as a potential 
candidate combination therapy is that clinical studies indicate that the concentrations 
evaluated in vitro are physiologically achievable in vivo [176, 244, 245]. In a Phase II 
clinical trial, steady state plasma levels from 0.61 µM to 14.6 µM were achieved in 
patients using twice-daily dosing of oral 4-HPR capsules (900 mg/m2) [244]. 
Furthermore, this dosage was well tolerated by all patients enrolled in the trial [244], and 
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additional Phase I trials are currently being conducted on improved oral formulations 
which increase 4-HPR-bioavailablity in order to extend the clinical benefit to a 
significantly greater number of patients [245, 246]. One additional factor to consider is 
that the steady-state levels of 4-HPR in breast tissue have been reported to be greater than 
those in plasma for a variety of doses [247] providing further evidence that the 
concentrations tested in vitro are likely to be clinically achievable. Additionally, the 
relatively low dose of Pal, which is non-toxic alone and well within the physiological 
range [248], was effective in enhancing 4-HPR-induced toxicity suggesting that this 
combination is likely to be well-tolerated by patients.  
An investigation into the biological basis of the ability of Pal to enhance 4-HPR-
mediated cell death suggests that the mechanism of action is much more complex than 
originally imagined. Surprisingly, Pal treatment alone, as well as the combination of Pal 
and 4-HPR, minimally affected or decreased the total cellular accumulation of (DH)Cer 
in MCF7 cells (Chapter 4; Fig. 4.7).  This was unexpected, particularly for Pal treatment 
alone, due to the known ability of Pal to increase flux through the biosynthetic pathway 
[145, 202]. However, it is possible that the exogenously added Pal is rapidly taken up and 
used for de novo biosynthesis within the first six hours of administration, as has been 
previously reported by Haynes, et al [249]. Following the initial “burst” of SL 
production, the newly synthesized lipids, including (DH)Cer and possibly (DH)SM, 
become components of membrane vesicles, such as exosomes, where they are released 
into the extracellular milieu for signaling purposes (as discussed in Chapter 4). This 
recommends future experiments to analyze the time-dependent effects of Pal alone and 
Pal in combination with 4-HPR on the intracellular SL composition, as well as the SL 
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composition of the exosomes released from MCF7 cells. Furthermore, it will be 
interesting to determine if the combination of Pal and 4-HPR exploits exosome release 
for delivering pro-death signals to neighboring cells as a mechanism to increase cellular 
toxicity. This idea is intriguing as it could be effective in explaining not only the 
enhanced cytotoxicty seen following treatment with Pal and 4-HPR, but also the lack of 
cytotoxicty following treatment with Pal alone. The Pal-induced release of exosomes did 
not result in significant cellular toxicity in a rat adipocyte cell model used for study [216], 
which is in agreement with the findings in Chapter 4 of the inability of Pal alone to 
induce toxicity in MCF7 cells (Chapter 4; Fig. 4.6). Furthermore, it was found that the 
addition of exosomes derived from untreated BT-474 breast cancer cells bound to the cell 
surface and actually stimulated the proliferation of parental BT-474 cells [212]. This idea 
agrees with the ability of Pal alone to slightly increase viability of MCF7 cells after 24 h 
of stimulation (Chapter 4; Fig. 4.6). Additionally, this concept may provide a novel part 
of the mechanism for the enhanced cell death observed following combination treatment 
with Pal and 4-HPR. It has been suggested that exosomes may bear different 
combinations of ligands dependent on cellular conditions [211]. Therefore, it is possible 
that the while Pal alone stimulates the release of (DH)Cer-enriched exosomes, the 
addition of 4-HPR alters the contents of these vesicles resulting in the transfer death 
inducing molecules, such as FasL, to neighboring cancer cells ultimately stimulating a 
second cell death response, likely necrosis [211]. Further support for this idea is provided 
by three independent studies reporting: (1) the ability of 4-HPR to upregulate the cell 
surface expression of Fas [250], which is expected to prime cells for activation of cell 
death by FasL, (2) the ability colorectal cancer cells to release exosomes containing FasL 
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that induce cell death in neighboring cells [211, 251], and (3) the ability of FasL to 
stimulate caspase independent cell death (CICD) with necrotic features when caspases 
are inhibited [252], such as the case in caspase-3 defective MCF7 cells used for this 
study. Further support for this idea is provided by the inability of Pal addition to enhance 
4-HPR-mediated autophagy and presumably autophagic cell death (Chapter 4; Fig. 4.8).  
A second possible contributor to cell death that has been found to be activated by 
both Pal [253-255] and 4-HPR [191, 256] is the production of ROS. Pal is known to 
stimulate a small accumulation of ROS in MCF7 cells [203]. Although, Pal-induced ROS 
accumulation is not sufficient to induce cell death in MCF7 cells [203], it is likely that 
the addition of 4-HPR, which also has been shown to generate ROS [100, 172], could 
enhance this accumulation to a level sufficient to create mitochondrial dysfunction 
resulting in necrosis. Distinguishing between these two possible mechanisms of 
activation of necrosis by comparing the effect of concurrent treatment with Pal and 4-
HPR with the effect of purified exosomes derived from concurrent treatment with Pal and 
4-HPR on MCF7 cells is an interesting area for continued investigation.  
Although these ideas seem intriguing, it is possible that the mechanism of 
enhanced 4-HPR-cytotoxcity following the addition of Pal is not due to the formation of 
Cer-containing exosomes or related to the production of ROS, but instead due to the 
species-specific functions of DHCer (as discussed above). One of the most interesting 
findings from the study in Chapter 4 was the differential regulation of Pal and OA on the 
distribution of the subspecies of DHCer (Chapter 4; Fig. 4.7), which correlated with 
opposing functions on 4-HPR-induced cell death (Chapter 4; Fig. 4.6). Therefore, it 
would be interesting to determine the effects of upregulating or inhibiting various CerS 
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family members on 4-HPR-induced toxicity in the presence of Pal or OA. Furthermore, 
the ability of different subspecies of DHCer to regulate intracellular signaling associated 
with cell death in combination with the ability of SL-enriched exosomes to participate in 
intercellular signaling processes is an exciting idea that may provide a synergistic 
mechanism for the enhanced cell death seen following the addition of Pal to 4-HPR-
treatment. Additionally, with regard to the potential regulation of cell death activation via 
SL signaling, the possible contribution of changes in Sa should not be omitted. In MCF7 
cells, 4-HPR increases Sa levels (Fig. 4.4). Furthermore, the elevation of Sa has been 
hypothesized to participate in 4-HPR-induced cytotoxicity in some cell systems [176]. 
Therefore, it is possible that Pal enhances 4HPR-induced cytotoxicity due to futher 
increases in Sa. This is currently an active area of investigation within the lab. Although 
the mechanism is no doubt the result of a surprisingly unexpected level of complexity, 
the ability of Pal to enhance 4-HPR-induced cell death provides evidence that the strategy 
of combining Pal-induced SL biosynthesis during lipotoxicity with chemotherapeutic 
agents may be clinically effective in increasing the single agent efficacy of 4-HPR (Fig. 
5.1C).   
 In conclusion, the studies described in this thesis have provided a more 
comprehensive picture of the cellular effects of KLA and 4-HPR on SL metabolism and 
regulation of the autophagic pathway, as well as investigated a novel strategy for the 
enhancement of current cancer therapies (Fig. 5.1). Through the use lipidomic 
technologies, genomic analysis, and cellular biology techniques, these studies have 
uncovered potentially interesting links between SL metabolism, autophagy, and other 
cellular behaviors, and it is hoped that these findings will prove informative in leading 
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future researchers to design new strategies for the treatment of infection, cancer, and 
other diseases. 
Figure 5.1 Summary 
A, Changing view of macrophage activation B, Changing view of the ability of 4-HPR to regulate SL 
metabolism C, New strategy for the enhancement of current cancer therapies based on SL paradigms  
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